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ABSTRACT 
 
Background:  Non-invasive prenatal testing (NIPT) is currently offered for the detection of 
Trisomy 21, 13, 18 and sex chromosome aneuploidy.  The test is unique because it reaches 
nearly diagnostic levels of accuracy, otherwise achieved only by invasive procedures like 
chorionic villus sampling or amniocentesis, but requires only a sample of maternal blood.  The 
NIPT technology continues to advance and a greater variety of genomic alterations can be 
detected.  This research study describes the detection of two different fetal microdeletions using 
NIPT, which includes whole genome next-generation sequencing, and targeted region capture 
and sequencing methods. 
Methods:  Whole genome next-generation sequencing, and targeted region capture and 
sequencing methods, were used on samples of maternal plasma obtained from pregnancies with 
confirmed microdeletions.  The DNA of these samples was compared to control DNA libraries to 
identify the fetal microdeletions. 
Results:  We were able to identify statistically significant differences between samples to detect 
fetal microdeletions on chromosome 12p12.1-p11.22 from maternal plasma samples.  
Identification of a fetal microdeletion on 5p15.33 from maternal plasma samples was achieved, 
but highlighted the difficulties in detection, and future challenges for NIPT. 
 iv 
Conclusion:  Our research has demonstrated the ability to detect microdeletions by whole 
genome next-generation sequencing and targeted region capture and sequencing methods of 
NIPT.  The findings indicate the ability of NIPT to detect a wide range of genomic alterations, 
which will impact prenatal care in the future if the technology improves.  Development and 
expansion of NIPT has significant public health implications due to its high levels of accuracy as 
compared to current screening, and safety for the pregnancy as compared to current diagnostic 
testing options.  NIPT could have major ethical implications, and could impact the role of 
prenatal genetic counselors and physicians. 
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1.0  INTRODUCTION 
Pregnancy screening and testing options have been clinically available to women for many years.  
Different methods have been employed, including ultrasound imaging, blood tests for a variety 
of molecular markers, and invasive procedures used to analyze fetal chromosomes.  As 
technology advances, new methods are being introduced to detect a variety of genetic conditions 
during pregnancy. 
One of the newest clinical pregnancy screening tests is called non-invasive prenatal 
testing (NIPT).  This technology screens for cases of fetal Trisomy 21, Trisomy 18, Trisomy 13, 
and sex chromosome aneuploidy.  The test is unique because it reaches nearly diagnostic levels 
of accuracy otherwise only achieved by invasive procedures like chorionic villus sampling 
(CVS) or amniocentesis, but requires only a sample of maternal blood.  As NIPT’s technology 
advances, a variety of genetic alterations can be detected.  This thesis describes two cases of 
microdeletions detected using NIPT, and describes the future of the technology, and the ethical, 
clinical, and professional implications of its use. 
1.1 AIM 
The goal of this paper is to demonstrate the ability to detect microdeletions by NIPT.  The 
methodologies of NIPT procedures have advantages and disadvantages, which will be discussed 
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in order to establish a review and guide future optimization of methodology.  There are public 
health, ethical, and genetic counseling implications with regard to NIPT’s use in the clinical 
setting. 
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2.0  BACKGROUND AND SIGNFICANCE 
2.1 GENETICS 
Human cells contain 46 chromosomes, which serve as the body’s guide for growth and 
development.  The 46 chromosomes are composed of 22 pair of autosomes and one pair of sex 
chromosomes, discovered by Tjio and Levan in 1956 [1].  Chromosome pairs are formed by 
combining one maternal and one paternal copy of each chromosome during egg fertilization.  
Chromosomal abnormalities may occur in 20-50% of all pregnancies [2].  Aneuploidy describes 
the condition where there is an extra chromosome (trisomy), or a missing chromosome 
(monosomy), caused by an error in meiosis or mitosis.  The most common cause of aneuploidy 
in pregnancy is nondisjunction during the first meiotic division in female gametes [3].  
Nondisjunction occurs randomly, but rates have been shown to increase with maternal age.  
Trisomy is the most commonly identified aneuploidy, occurring in about 4% of all pregnancies, 
and 27% of miscarriages, with miscarriage occurring in 15% of recognized pregnancies [1, 4].   
Trisomy 21, also called Down syndrome, is caused by an extra chromosome 21.  The 
condition was first recognized by Lejeune in 1959 [1].   Trisomy 21 occurs sporadically in about 
95% of cases, but at the age of 35, the chance for a fetus to have Trisomy 21 is 1/270 [5].  Down 
syndrome may also be caused by a Robertsonian translocation that becomes unbalanced, which 
accounts for about 5% of cases.  Individuals can be carriers of Robertsonian translocations 
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without having a personal or family history of Down syndrome.  The characteristic phenotype of 
Down syndrome includes developmental delay, mild to moderate intellectual disability, 
hypotonia, and characteristic facial features.  Occasionally heart defects and gastrointestinal 
defects are identified.   
Trisomy 13, or Patau syndrome, and Trisomy 18, or Edwards syndrome are two other 
trisomies that are commonly seen among women of advanced maternal age.  Both of these 
conditions are more rare and severe than Down syndrome.  Patau syndrome often includes severe 
intellectual disability, cleft lip and palate, and nervous system anomalies.  Edward's syndrome 
can include severe intellectual disability, heart defects, and nervous system anomalies.  In many 
cases, Patau and Edwards syndromes are not compatible with life, and many affected fetuses are 
spontaneously aborted, or die shortly after delivery. 
Other common trisomies include sex chromosome aneuploidy.  Included are monosomy 
X, or Turner syndrome, XXY or Klinefelter syndrome, XXX, and XYY, which range in 
phenotypic presentation.  Turner syndrome is associated with short stature and lack of secondary 
sexual development.  Klinefelter syndrome’s phenotype includes infertility, tall stature, and 
learning difficulties.  XXX and XYY both are associated with learning and behavioral 
difficulties [3]. 
Other structural chromosome changes may occur in pregnancy, regardless of maternal 
age.  Deletions and duplications are missing or extra pieces of genetic material as large as an 
entire chromosome, or as small as a single base pair.  Duplications of genetic material are 
typically less pathogenic, and have fewer phenotypic findings, while large deletions have a 
stronger effect on phenotype [1, 3].  Microdeletions and microduplications typically describe 
alterations too small to be detected by standard karyotype analysis.  Microdeletion syndromes 
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can be found on many chromosomes, and they have extremely variable expression and range of 
phenotypic features depending on the genes involved.  Deletions and microdeletions may occur 
when genetic material is rearranged, such as during an inversion or translocation, or 
spontaneously as a de novo mutation.  Deletions and microdeletions can be inherited from an 
apparently unaffected parent before being expressed in a child, due to differences in disease 
penetrance, expression, genomic imprinting, other comorbid genetic changes, or for unknown 
reasons. 
Deletions and duplications are not as common as aneuploidy, and their occurrence does 
not follow an age related trend in pregnancies.  Currently, these genomic changes are not 
regularly screened or tested for in pregnancy.  Since aneuploidy is more common, and the risk 
increases with maternal age, there are screening and diagnostic tests available to determine the 
fetal risk or status for the chromosome conditions described above. 
2.2 CURRENT PRENATAL SCREENING AND DIAGNOSIS 
2.2.1 Non-invasive Prenatal Screening Options 
There are three non-invasive screening options for the assessment of fetal risk for a chromosome 
condition.  Screening tests are used to assess risk or predict disease [6].  These screening tests 
include first trimester screening, multiple marker screening, and ultrasound imaging.  
Understanding the methodology, benefits, and limitations of these screening options is important 
for the comparison to NIPT. 
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First trimester screening and multiple marker screening consider maternal age and 
gestational age.  Maternal age is the age of the patient’s eggs, so caution must be used in cases of 
IVF pregnancies using donor eggs.  Gestational age can be measured using last menstrual period 
(LMP), ultrasound measurement of crown rump length in the first trimester, biparietal diameter 
(BPD) in the second trimester, or physical exam dating.  Dating of the pregnancy is crucial for 
accurate screening.   
First trimester screening is a noninvasive pregnancy screening test that became widely 
used in the 1990s.  It combines ultrasound and blood testing between 11 and 14 weeks gestation 
to determine the risk for Down syndrome and Trisomy 18.  The nuchal translucency (NT) is 
assessed by ultrasound visualization.  The best time to obtain an accurate measurement of the 
nuchal translucency is between 11 weeks and 13 weeks 6 days gestation [7].  When increased 
nuchal translucency is detected, one third of cases are found to have a chromosomal abnormality, 
of which, 75% have Trisomy 21 or Trisomy 18.  Increased NT measurements have been 
associated with fetal cardiovascular and pulmonary defects, skeletal dysplasia, congenital 
infection, metabolic disorders, and hematologic disorders [7, 8].  The blood test measures the 
relative amounts of pregnancy-associated plasma protein A (PAPP-A) and free beta (or total) 
human chorionic gonadotropin (hCG).  The amounts are reported as multiples of the median 
(MoM), which may vary by center [9].  In pregnancies where the fetus has Trisomy 21, hCG is 
increased and PAPP-A is decreased and for Trisomy 13 and 18, hCG and PAPP-A are decreased.  
Other chromosome conditions may be detected using first trimester screening information, but 
they are not regularly offered.   
Ultrasound and blood measurements are combined to determine the risk for the 
pregnancy.  Cut-off values have been determined: an increased risk for Down Syndrome is > 
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1/230, and an increased risk for Trisomy 18 is > 1/100 [9].  First trimester screening detects 85-
90% of cases of Down syndrome, with a false positive rate around 5% [5, 7, 10].  There are no 
risks to the pregnancy with this screening, but the results are not diagnostic, and only Down 
syndrome and Trisomy 18 are detected.  For twin gestations, the NT is measured for each fetus, 
but the blood sample analysis is averaged between the two fetuses, thus is less accurate in 
predicting the likelihood of an affected fetus.  In pregnancies with greater than two fetuses, NT 
measurements are the only reliable method of screening for chromosomal abnormalities [7]. 
Multiple marker screening, also called quadruple screening, was introduced in the 1980’s 
and is a noninvasive pregnancy screening test done in the second trimester, between 15 and 20 
weeks gestation [11].  Blood is analyzed for alpha-fetoprotein (AFP), total hCG, unconjugated 
estriol (uE3), and Inhibin-A.  When Inhibin-A is not included, this screening is called Triple 
screen.  These molecules are measured to determine a relative risk for an open neural tube defect 
(ONTD), Down syndrome, and Trisomy 18.    
The pattern detected by multiple marker screening is used to determine the pregnancy 
risk.  Low AFP, low uE3, high hCG, and high Inhibin-A indicate an increased risk for Down 
syndrome.  Low levels of AFP, hCG, and uE3 indicate an increased risk for Trisomy 18.  Triple 
and Quad screens adjust the risk based on maternal age and maternal weight. A screening 
assessment of >1/270 is considered increased risk for Down syndrome [9].  Second-trimester 
quadruple screening detects about 81% of cases of Down Syndrome, 60% of Trisomy 18, 80% of 
cases of spina bifida, 90% of cases of anencephaly, 80% of abdominal wall defects, and 60% of 
ONTDs in twin pregnancies with a 5% false positive rate [9, 12].  Screening for Trisomy 18 in a 
twin pregnancy is currently not possible.  Occasionally uE3 is undetectable, which has been 
associated with fetal demise, IUGR, anencephaly, and genetic syndromes that are related to 
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cholesterol biosynthesis pathways including congenital adrenal hypoplasia, Smith-Lemli-Opitz 
syndrome, and steroid sulfatase deficiency [13]. 
Different screening algorithms have been proposed which define when to collect 
pregnancy information, how to synthesize the data, and when to report the results.  Stepwise 
sequential screening gives the pregnancy risk results after each screening test.  Contingent 
sequential screening allows further screening to be canceled if the first trimester screen is 
negative.  Fully integrated screening gives a single result combining both first and second 
trimester screening [14].  Serum integrated screening also only gives a single result, but does not 
use NT measurement in its calculations [12].  Studies have found that fully integrated screening 
detects 94-96% of cases of Down syndrome, and integrated screening with serum detects 85-
88% [12, 14, 15].  Integrated screening’s major disadvantage is that it requires second trimester 
screening results, thus limiting access to CVS procedures.  Sequential screening allows for 
earlier results, and combines the first and second trimester measurements into a final risk 
assessment. 
The third method of non-invasive prenatal screening is ultrasound.  There are three types 
of ultrasound examinations: standard or basic, limited, and specialized or detailed.  Specialized 
ultrasounds are performed when there is a suspected fetal anomaly based on laboratory 
abnormalities, medical history, or family history.  Specialized exams may include fetal Doppler 
ultrasonography, biophysical profile, amniotic fluid assessment, fetal echocardiography, or 
biometric measurements [16].  A detailed anatomy ultrasound is typically performed between 18 
and 20 weeks gestation, and looks at the fetal head, face, neck, chest, heart, abdomen, spine, 
extremities, and sex.  Anatomy ultrasound can detect 50% of cases of Down Syndrome, and 
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greater than 90% of cases of spina bifida and anencephaly [5, 16].  Overall, ultrasound 
examination detects 40% of fetal anomalies with variation between centers [16]. 
Ultrasound findings associated with Down syndrome include: increased NT, hyperechoic 
bowel, shortened humerus, echogenic intracardiac focus, shortened femur, and pyelectasis [17].  
Echogenic intracardiac focus is one of the most common isolated markers in both healthy fetuses 
and those affected with Down syndrome.  Ultrasound findings for Trisomy 18 can include IUGR, 
heart defects, strawberry shaped calvarium, clenched fists, rockerbottom feet, micrognathia, cleft 
lip or palate, omphalocele, diaphragmatic hernia, neural tube defect, cystic hygroma, 
polyhydramnios, and choroid plexus cysts [9].  Approximately 75% of fetuses with cystic 
hygromas by ultrasound have a chromosome abnormality, and of these, 95% of cases have 
Turner syndrome. When nuchal edema (or increased NT) is detected, one third of cases are 
found to have a chromosomal abnormality, of which, 75% have Trisomy 21 or Trisomy 18.  Due 
to the limitations of ultrasound examination, it is not recommended as a primary method of 
screening for Down syndrome or other chromosome conditions. 
2.2.2 Invasive Prenatal Diagnosis Options 
There are two invasive diagnostic procedures available to women during pregnancy.  These 
procedures include chorionic villus sampling (CVS) and amniocentesis which allow for the 
isolation of fetal cells.  These cells can be directly analyzed or cultured in the laboratory for 
detection of genetic conditions by karyotyping, FISH analysis, or other molecular testing 
including microarray analysis.  These methods are considered greater than 99% accurate.  
Previously, only women who were considered “high risk” were offered invasive procedures, but 
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now ACOG recommends that all women, regardless of age, be offered the option of invasive 
prenatal testing [14].  
Chorionic villus sampling (CVS) is an invasive procedure performed between 10 and 12 
weeks gestation that collects chorionic villi tissue, which is part of the placenta.  Under 
ultrasound guidance, a catheter is used transvaginally, or a needle is inserted transabdominally to 
collect tissue samples.  There is a risk of miscarriage with the procedure ranging from 1/200-
1/1000, depending on the center where the procedure is performed, and the expertise of the 
individual performing the procedure.  The risk for miscarriage extends approximately two weeks 
beyond the date of the procedure for CVS and amniocentesis.  Rapid FISH results for 
chromosomes 21, 13, 18 and the sex chromosomes can be obtained 24-48 hours following the 
procedure.  Karyotype results typically take 10-12 days following the procedure.   
CVS is considered a more technically difficult procedure than amniocentesis, and 100-
400 procedures need to be performed by a physician before the learning curve reaches a plateau,  
compared to 30 procedures for amniocentesis [18, 19].  The miscarriage rate was found to be 
increased in centers performing fewer than 136 procedures per year [19, 20].  Individuals 
undergoing CVS typically will not need to have an amniocentesis.  One exception is in the case 
of placental mosaicism.  Mosaicism can occur within a tissue, multiple tissues, or an entire 
organism, and depends when during development nondisjunction occurred.  Mosaicism is 
detected in about 1% of CVS samples, and an amniocentesis is typically recommended to clarify 
the finding [1, 18].  
Amniocentesis is an invasive procedure performed after 15 weeks gestation.  A needle is 
inserted transabdominally to collect two tablespoons of amniotic fluid.  The cells obtained from 
the sample, amniocytes, are shed by the fetus.  FISH and karyotype results following 
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amniocentesis take the same period of time to be reported as the results from CVS.  There is a 
risk of miscarriage with the procedure ranging from 1/200-1/1000 when completed before 22 
weeks gestation, and a risk of preterm labor from 1/200-1/1000 after 22 weeks gestation [5, 21].  
Other risks of the procedure may involve leakage of amniotic fluid, membrane rupture, bleeding, 
infection [22].  The risk for miscarriage was found to be increased in centers performing fewer 
than 45 procedures per year [19].  Diagnostic error may occur in cases of maternal cell 
contamination or low level mosaicism [18]. 
Samples obtained by CVS and amniocentesis are sent for standard karyotyping and FISH 
analysis.  Karyotypes allow for the chromosomes to be visualized, counted, and analyzed for 
translocations, inversions, ring chromosomes, missing or extra chromosomes, and other 
structural changes, and can detect low level mosaicism that may be missed using other methods.  
FISH analysis uses fluorescently labeled probes that attach to specific chromosome regions, 
which can be counted to determine if the region is missing or replicated.  Cytogenetic analysis 
typically detects changes at or above the resolution of 5 to 10Mb, and requires live cells to 
culture for analysis [23].  FISH and karyotype are considered the standard of care for prenatal 
diagnosis, but improvements in technology have given patients and physicians new options for 
obtaining a prenatal diagnosis.  The most recent and debated methodology is microarray 
analysis. 
Microarray analysis is used to detect small imbalances in the chromosomes, called copy 
number variants (CNV), including deletions and duplications that are at least 1Kb in size [24].  
The technology is considered standard of care, with karyotype analysis, in the pediatric setting as 
12-15% of children with normal karyotype analysis have been found to have a genetic change by 
microarray [25].  Microarray analysis has only recently been used in the prenatal setting.  Some 
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benefits of using microarray include decreased time to obtain results, as samples do not need to 
be cultured in the lab, and detection of clinically relevant deletions and duplications that would 
have been missed by karyotype analysis.  One study found that microarray provided relevant 
information to an additional 1.7% of pregnancies tested due to advanced maternal age and 
positive screening results, and an additional 6.0% of pregnancies tested due to ultrasound 
findings.  Microarray analysis could be used to diagnose stillborns, where genetic abnormalities 
are found in 6-13% of cases [23].  One benefit to using microarray on stillborns is that growing 
tissue is not required for analysis.  One disadvantage is that 3.4% of microarray findings are 
considered variants of uncertain significance, of which, 72.3% were not easily classified as 
benign [25].  Other disadvantages of microarray testing in the prenatal realm include limited 
ability to detect triploidy, balanced translocations, marker chromosomes, low level mosaicism, 
and the lack of clinical findings to correlate to variants of uncertain significance.  The cost of 
microarray analysis is higher and may not be proportional to the clinically useful information 
gained [24].  As the debate over the use of microarray analysis in the prenatal setting continues, 
new technologies are being introduced in the pediatric setting, including whole-exome and 
whole-genome sequencing.  These technologies could be applied to the prenatal setting in the 
future, and may be able to detect an even greater number of genetic alterations than cytogenetic 
or microarray technologies.  The benefits and disadvantages of these technologies will be 
discussed further, as they apply to the ethics and clinical challenges related to prenatal testing 
and diagnosis. 
Amniocentesis and CVS are valuable options for genetic diagnosis during pregnancy, but 
the risk of miscarriage, physical discomfort, and anxiety of undergoing an invasive procedure are 
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deterrents for many women and families.  The disadvantages of invasive diagnostic options 
highlight the potential benefits of non-invasive prenatal testing. 
2.3 NON-INVASIVE PRENATAL TESTING 
2.3.1 History of Non-invasive Prenatal Testing 
Non-invasive prenatal testing originated from cancer research and tumor genetics.  Researchers 
discovered tumor DNA in the plasma and serum of cancer patients’ blood in 1996.  In 1997, Lo 
et al. hypothesized that fetal DNA could be detected in a pregnant woman’s blood.  Lo et al. 
detected fetal Y chromosome DNA in 80% of maternal plasma and 70% of maternal serum from 
women carrying male fetuses, using PCR assays for the Y chromosome [26].  The average fetal 
DNA concentration in maternal plasma was 3.4% in the first trimester and 6.2% during the 
second and third trimesters [27].  Cell free fetal DNA had a half life of sixteen minutes, and was 
not detected in maternal circulation two hours after delivery [28].     
The source of fetal DNA, and why there was an increase in concentration during the 
pregnancy was not determined until 2004.  Gupta et al. found that fetal DNA and RNA were in a 
cell-free form in the maternal plasma, originating from the placenta.  Gupta proposed that 
apoptotic release of syncytiotrophoblast membrane of the placenta explained the circulating fetal 
DNA that had been detected, and that preeclampsia was proposed to correlate with increased 
levels of cell-free fetal DNA [29].  Preterm delivery was associated with increased 
concentrations of cell-free fetal DNA in maternal circulation [30]. 
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In 1999, fetal DNA in maternal circulation was used to determine fetal rhesus D (RhD) 
status.  RhD status is significant for RhD-negative women carrying an RhD-positive fetus, as the 
mother’s immune system may reject the antibodies produced by the fetus [31].  In the UK anti-D 
is given to all RhD-negative pregnant women, although 40% carry RhD-negative fetuses and do 
not require the prophylaxis.  Previously, RhD status was detected by sampling fetal blood or 
amniocentesis.  Determination of the fetal RhD status could prevent unnecessary medical 
interventions, and reduce exposure to hepatitis C and prion diseases by reducing anti-D 
injections [32].   
Other novel uses of NIPT technology were discovered in the 2000’s.  In 2005, 
hemoglobinopathies were detected by NIPT, but methodologies were too complex for testing to 
be implemented clinically [33].  Fetal sex had been detected by NIPT, since male fetal DNA 
markers on the Y chromosome were used to measure fetal DNA concentration.  Some groups 
proposed offering sex determination testing clinically for individuals at risk for X-linked genetic 
conditions [34].  Achondroplasia was detected using NIPT in 2007 [35, 36].  NIPT has the 
capability to include paternity testing, detection of single gene disorders, aneuploidy, 
microdeletions, and microduplications. 
Tong et al. first proposed using NIPT to detect fetal aneuploidy.  In 2006, the group used 
epigenetic allelic ratio analysis for chromosome 18.  The ratios between fetal and maternal allele 
concentrations were calculated using Maspin sequences found on chromosome 18.  The ratio was 
used to compare differences between euploid and Trisomy 18 fetuses [37].  Tong’s discovery 
began the use of NIPT for fetal aneuploidy detection, now offered clinically for Trisomy 21, 
Trisomy 18, Trisomy 13, and sex chromosome aneuploidy. 
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2.3.2 Methods of Non-invasive Prenatal Testing 
Several methods have been proposed in the development of NIPT.  Researchers searched for 
ways to improve methods of fetal DNA detection by searching for reliable markers to quantify 
and distinguish fetal DNA from maternal DNA, and by testing new technology.  Early NIPT 
only accurately tested male fetuses due to limitations of distinguishing fetal and maternal DNA.  
To study male and female fetuses, a universal marker for fetal DNA should be non-gender 
specific, applicable to all ethnicities and population groups, easily detectable, sufficiently cleared 
from maternal circulation following delivery, and unique to the fetal DNA (verses maternal 
DNA).   
One of the first universal markers proposed was Maspin; a tumor suppressor gene on 
chromosome 18.  Maspin is expressed and hypomethylated in placental tissue, but methylated in 
maternal blood [37].  The detection of methylation patterns was challenging due to bisulfate 
conversion and DNA degradation.  A second epigenetic fetal DNA marker was RASSF1A on 
chromosome 3p21.3, which is hypermethylated in placental tissue and hypomethylated in 
maternal blood.  RASSF1A methylation status was detected using methylation-sensitive 
restriction enzyme digests which were more reliable and sensitive than bisulfate based methods 
[38].  HLCS was discovered on chromosome 21, and is hypermethylated in placental tissue and 
hypomethylated in maternal blood [39].  Single nucleotide polymorphisms (SNPs) have also 
been used as markers.  SNPs are benign base pair changes that occur once every 300 nucleotides, 
and make up approximately 90% of genetic variation in humans [40, 41].  There are 
approximately 10 million SNPs in the human genome, and SNP frequency relies upon the 
population of interest, as SNPs are more variable between different ethnicities and regional 
groups [28, 41].  One SNP used in NIPT is in the PLAC4 gene, and is transcribed from 
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chromosome 21 only in placental cells [42].  Methylation pattern differences between fetal and 
maternal DNA can be distinguished using methylated DNA immunoprecipitation coupled with 
oligonucleotide array analysis.  The advantages of this technique include genome wide 
screening, gender and SNP independence, and lack of DNA degradation, unlike bilsufite 
methods [43]. 
Polymerase chain reactions (PCR) and quantitative real-time PCR (q-RT PCR) were first 
used to identify and quantify fetal DNA in maternal blood, but challenges arose due to the 
variable concentration of cell-free fetal DNA.  One strategy was to enrich samples, or increase 
the relative concentration of cell-free fetal DNA in blood.  Size fractionation was proposed when 
Li et al. determined that fetal DNA sequences are smaller (< 300 base pairs) than circulating 
maternal DNA (> 500 base pairs) [33].  About 80% of cell free fetal DNA is less than 193 base 
pairs in length [28].  Size fractionation was challenging when maternal blood samples were held 
over a period of time, allowing maternal blood cell apoptosis which increased the ratio of 
maternal DNA fragments.  Formaldehyde was used as an inhibitor of maternal blood cell 
apoptosis to keep the fraction of fetal DNA consistent [28].  Enrichment may also be achieved by 
targeting fetal specific genetic or epigenetic sequences as markers [43]. 
Several forms of technology have been used to develop NIPT.  Li  et al used mass 
spectrometry to analyze samples, which measured the mass of each DNA fragment to elucidate 
the sequence and detect allelic changes [28, 33].  Chiu et al. proposed massively parallel 
genomic sequencing and locus targeting, which measured the total maternal and fetal DNA for a 
specific chromosomal locus using digital PCR.  Incremental changes in the ratio of chromosomes 
were used to detect trisomies [44].   
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One study considered two possible research-based approaches to NIPT in 2010: analysis 
of allelic ratios of SNPs in a fetal specific marker including analysis of circulating placental 
mRNA (RNA-SNP approach) or DNA-methylation markers (epigenetic allelic-ratio approach), 
with single molecule counting methods including digital PCR, microfluidics digital PCR, and 
massively parallel genomic sequencing [39, 45, 46].  High-throughput shotgun sequencing was 
used to detect aneuploidy by Fan et al.  Shotgun sequencing did not rely on SNPs, and provided a 
uniform application of the technology.  Variation in GC content of different chromosomes 
effected sequence counts between samples, and caused imprecise measurements when using 
sequencing methods [43, 47].  Chiu et al. described a way to identify chromosomal origin of 
each sequenced DNA molecule using massively parallel sequencing by comparing the nucleotide 
sequence with the reference human genome.  In euploid fetuses, 1.35% of all fragmented DNA is 
contributed by chromosome 21 [48].  By comparing the genomic representation of specific 
chromosomes, like chromosome 21, the degree of deviation from the expected genomic 
representation could be determined and statistically analyzed.  This method using sequencing-by-
ligation showed less bias for chromosomes with low GC content [49, 50]. 
Different methods and analytical frameworks are being developed to accurately detect 
genetic alterations in cell-free fetal DNA.  New developments focus on novel methods of 
enrichment, correcting for GC content of different chromosomes, decreasing costs, and 
optimizing technology.  This thesis will describe some developments in the field of NIPT with 
regards to detection of fetal microdeletions. 
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2.3.3 Current NIPT Clinical Testing 
There are currently four clinical laboratories offering NIPT; Verinata (Verifi), Sequenom 
(MaterniT21), Ariosa (Harmony), and Natera (Panorama).  Each lab has specific methods, test 
sensitivity, and specificity.  Magee-Womens Hospital in Pittsburgh, Pennsylvania offers NIPT to 
“high risk” pregnancies including advanced maternal age, abnormal serum screen result, 
personal or family history of genetic condition, and/or abnormal ultrasound.  Testing is offered 
any time after ten weeks gestational age to women with singleton pregnancies.  Before having 
NIPT, patients meet with a genetic counselor to discuss the technology, what is being tested for, 
the risks and benefits, costs, and how results will be reported.  Follow up testing with CVS or 
amniocentesis is recommended if positive results are obtained.  Currently, Magee-Womens 
Hospital offers NIPT through Verinata. 
Verinata was one of the first three companies to publish validation studies.  In April 
2011, Sehnert et al. published a trial of their massively parallel DNA sequencing study to detect 
fetal Trisomy 21 and Trisomy 18.  The research included 1014 patients from 13 clinics across the 
United States who were at least 18 years of age.    There were 71 controls and 48 samples in the 
test set.  Sequencing libraries were created with single-end reads of 36bp.  Sequencing variation 
was controlled by calculating the normalized chromosome ratio of mapped sites for a given 
chromosome to counts observed on a predetermined chromosome. The mean and standard 
deviation for the training set libraries and the samples were used to calculate the normalized 
chromosome value (NCV), which is equivalent to a z-score for the ratios for each chromosome 
of interest.  An NCV >4.0 was required to classify results as aneuploidy, and <2.5 to classify as 
unaffected.  Trisomy 21 was accurately detected in the control and test sets (NCVs 5-14), 
Trisomy 18 in most cases (NCVs 3.3-22), and Trisomy 13 was not accurately detected (NCV’s 
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“no call” through 4) [51].  Information was collected across the genome, so copy number 
variation and cases of mosaicism were detectable.  In order for massively parallel sequencing 
methods to be efficient, algorithms must be able to account for random or systematic bias in 
sequencing by normalization.  Compared to methods previously described by Chiu et al., which 
used sequence tag number on the chromosome of interest normalized by number of tags in the 
sequencing run, the previous study did not yield as precise data for detection of Trisomy 18 and 
Trisomy 13 as Sehnert’s study.  Sehnert et al. planned to improve methodology by developing 
sequencing run controls that measure baseline and can change based on sequencing behavior 
[51].  A validation study by Bianchi et al., called the MELISSA study, obtained samples from 60 
medical centers in the United States.  Recruitment was offered to pregnant women over the age 
of 18 who were between eight and 22 weeks gestational age, who met at least one criterion for 
high risk pregnancy.  Five hundred thirty two singleton pregnancies were selected, and cases of 
abnormal fetal karyotypes were matched to cases with euploid fetal karyotypes.  A total of 89 
cases of Trisomy 21, 36 cases of Trisomy 18, 14 cases of Trisomy 13, and 16 cases of 
Monosomy X were analyzed using massively parallel sequencing.  Cell free fetal DNA was 
quantified using two allele specific methods: one using nine short tandem repeat loci to compare 
intensity peaks (minor peaks represented fetal DNA), and a panel of 15 SNPs.  Control libraries 
were composed of 110 unaffected samples, separate from samples recruited for the study.  NCV 
calculations and thresholds for analysis were the same as the Sehnert study. The laboratory was 
blinded to the clinical information, so no adjustments were made for maternal BMI, smoking 
status, diabetes status, type of conception, prior pregnancies, prior aneuploidy, or gestational age.  
Results were as follows: 
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Table 1. Verinata's MELISSA Study Results 
Massively Parallel 
Sequencing Results 
Sensitivity 95% CI Specificity 95% CI 
Trisomy21  (n=493) 100.0% (89/89) 95.9-100.0 100.0% (404/404) 99.1-100.0 
Trisomy18 (n=496) 97.2% (35/36) 85.5-99.9 100.0% (460/460) 99.2-100.0 
Trisomy13 (n=499) 78.6% (11/14) 49.2-99.9 100.0% (485/485) 99.2-100.0 
XX (n=433) 99.6% (232/233) 97.6-99.9 99.5% (199/200) 97.2-99.9 
XY (n=433) 100.0% (184/184) 98.0-100.0 100.0% (249/249) 98.5-100.0 
Monosomy X (n=433) 93.8% (15/16) 69.8-99.8 99.8% (416/417) 98.7-99.9 
Adapted from Bianchi, D.W., et al., Obstet Gynecol, 2012. [52] 
NCV for Trisomy 21 ranged from 4-26 (one at four), Trisomy 18 NCV ranged from below 4 
to 16 (three below four), and Trisomy 13 ranged from below four to approximately 18 (five 
below four) [52].  Findings confirmed that fetal aneuploidy including translocation trisomy, 
mosaicism, and complex variation can be detected with high sensitivity and specificity, and 
aneuploidy in one chromosome does not affect the ability of massively parallel sequencing to 
identify euploid status of other chromosomes [52].  Verinata posted on February 15, 2013 that 
twin pregnancy chromosome abnormalities were accurately detected, which may indicate the 
future expansion of testing population [53].  Currently Verinata’s, Verifi offers testing for 
Trisomy 21, 13, and 18, and sex chromosome aneuploidy using a newly updated sequencing 
method.  Verifi uses the SAFeR algorithm for statistical analysis and does not exclude 
patients due to ethnicity, BMI, or egg donor status.  Patients must be at least 10 weeks 
gestational age and meet criteria for a high risk pregnancy.  Results take eight to 10 days, and 
testing sensitivity and specificity are quoted as: 
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Table 2. Verinata's Verifi Testing 
Chromosome N Sensitivity 95% CI Specificity 95% CI 
21 500 >99.9 (90/90) 96-100.0 99.8% (409/410) 98.7-100.0 
18 501 97.4% (37/38) 86.2-99.9 99.6% (461/463) 98.5-100.0 
13 501 87.5% (14/16) 61.7-98.5 >99.9% (485/485) 99.2-100.0 
Monosomy X 508 95.0% (19/20) 75.1-99.9 99.0% 97.6-99.7 
XX 508 97.6% (243/249) 94.8-99.1 99.2% (257/259) 97.2-99.9 
XY 508 99.1% (243/249) 96.9-99.9 98.9% (276/279) 96.9-99.8 
XXX,XXY,XYY Limited data 
Adapted from Verinata’s website [53] 
  
A second company, Sequenom, offers NIPT through MaterniT21.  Sequenom was the 
first company to offer NIPT clinically, in October of 2011 [54].  Ehrich et al. published a pilot 
study of multiplexed massively parallel shotgun sequencing for detection of Trisomy 21 in 480 
blood plasma samples from women with a high risk pregnancy.  Four libraries of DNA 
fragments were created and were analyzed together (multiplexed).  Each 36pb DNA fragment 
yielded 5 million copies.  Statistical analysis was modeled off of Chiu et al.’s previous work.  Of 
the samples collected, 40 Trisomy 21 cases were correctly identified.  The differences in this 
study compared to previous studies were that they used custom purified enzymes in the library 
generation process, a GAIIx sequencer with the CASAVA version 1.6 software, and indexing 
primers for library amplification to allow for multiplexing.  These alterations led to cost savings, 
increased sequence reads per lane, and more sequence reads per sample, totaling four times 
higher throughput for four times lower cost.  Overall, the study produced 100% sensitivity and 
>98% specificity [48].  Then Chiu et al. published a validation study of NIPT for Trisomy 21 
detection.  Samples were obtained from 753 women with high risk pregnancies in Hong Kong, 
the Netherlands, and the UK.  Samples were analyzed by multiplex massively parallel 
sequencing using 8-plex and 2-plex protocols, where the 2-plex protocol analyzed seven times 
more plasma DNA molecules.  The Z-score statistic was calculated with a cut off set at greater 
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than three to represent aneuploidy, representing the 99.9th percentile of the reference sample.  An 
average of 300,000 reads was obtained per sample for the 8-plex sequencing analysis, and 2.3 
million for the 2-plex sequencing analysis.  The 8-plex sequencing protocol was not as accurate, 
as some non-trisomy 21 were above the z-score cut off of three and some Trisomy 21 cases fell 
below the cut off.  The 2-plex protocol had fewer inaccuracies [55].  The study also explained 
that if fetal DNA concentration is approximately 10%, the percentage of chromosome 21 is 1.05 
times higher in a Trisomy 21 pregnancy than a euploid pregnancy.  To detect this change, the 
coefficient of variation of the test would need to be < 0.83%.  The 8-plex protocol was greater 
than 0.83%, while the 2-plex protocol was less than 0.83%, explaining the superior ability to 
detect Trisomy 21 in samples with low fetal DNA concentrations.  From the study, they 
concluded that NIPT for Trisomy 21 is best performed as a screening test for high risk 
pregnancies, and in individuals who are considering CVS and amniocentesis [55].  Palomaki et 
al. also performed a validation study of NIPT for detection of Trisomy 21 in 4664 high risk 
pregnancies.  The study determined that the detection rate was 98.6% with a false positive rate of 
0.2% [56].  In 2012, Sequenom moved toward validation studies of other chromosomal 
trisomies, like Trisomy 13 and Trisomy 18.  Palomaki et al. studied 62 pregnancies with Trisomy 
18 and 12 with Trisomy 13 to test the ability of the current technology to accurately identify 
these aneuploidies.  The total failure rate for testing (due to low fetal concentration and sample 
quality) was 0.9%.  Detection rate for Trisomy 18 cases was 100% with a false positive rate of 
0.3%.  For Trisomy 13, the detection rate was 91.7% with a false positive rate of 0.9%.  Repeat 
masking, which normalizes the GC content, was used to analyze cases of Trisomy 13 and 18, and 
showed no change in detection or false positive rates.  Overall, the study showed that Trisomy 
21, 13, and 18 can be accurately detected using NIPT [57].  Canick et al. studied the use of NIPT 
 22 
for multiple pregnancies.  They studied samples from a cohort of 4664 high risk pregnancies, 
which included 25 twin pregnancies (17 euploid, seven Trisomy 21, and one Trisomy 13), and 
two euploid triplet pregnancies.  The GC content bias was statistically corrected and the results 
showed that Trisomy 21 was correctly identified in all twin pregnancies with Down syndrome, 
and one Trisomy 13 case was correctly identified.  Multiple pregnancies contributed 35% more 
fetal DNA than singleton pregnancies, which is expected due to greater placental mass.  
Differences in fetal-maternal ratio of cell free fetal DNA arise when twins are discordant for 
chromosomal aneuploidy, and technical difficulties arise if the fetal DNA concentrations fall 
between four and six percent.  At the conclusion of the study, it was determined that definitive 
assessments of sensitivity of detecting trisomies could not be completed, and assessment of twins 
individually is not possible [58].  Currently, the clinical test, MaterniT21 reports the following 
for testing sensitivity and specificity: 
Table 3.  Sequenom's MaterniT21 Testing 
 
Study Chromosome N Sensitivity Specificity 
Ehrich et al. 2011 21 450 >99% (39/39) 99.7% 
Palomaki et al. 2011 21 1696 99.1% (210/212) 99.9% 
Palomaki et al. 2012 18 1988 >99.9% (59/59) 99.6% 
13 91.7% (11/12) 99.7% 
Canick et al. 2012 21 and 13 2015 >99.9% (8/8)  
ASHG Poster 2012 X and Y 2107 99.4%  
Adapted from Sequenom’s website [59] 
 
Ariosa is the third clinical NIPT lab, whose test is Harmony.  The lab’s first publication 
was by Sparks et al. in January of 2012.  The study collected samples from singleton 289 
pregnancies and sought to develop NIPT for the detection of Trisomy 21 and Trisomy 18 using 
DANSR (digital analysis of selected regions) by highly multiplexed assay.  The goal was to 
make the NIPT process more efficient by generating fewer unused sequence reads.  DANSR 
analysis is completed by using 384 loci on chromosome 18 and chromosome 21.  The loci are 
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unique to the chromosomes of interest and do not coincide with known polymorphisms or copy 
number variants.  There are three oligonucleotides per loci to amplify the regions of interest.  
After sequencing the regions, the median count per locus was scaled to 1000, and then log 
transformed to account for bias among chromosomes, loci, and samples to create a linear 
statistical model.  Data was used to calculate a z-test of proportions, and the separation distance 
was calculated as the distance between the z statistic value of the upper 95th percentile of 
average-risk samples and the lower 5th percentile in the affected samples.  Analysis of 
chromosome 21 showed a separation distance of 4.2 with 204,000 reads, 5.2 with 410,000 reads, 
and 5.4 with 620,000 reads.  For chromosome 18, analysis showed a separation distance of 4.9 
with 204,000 reads, 5.2 distance with 410,000 reads, and 5.2 with 620,000 reads.  With 
chromosome 18, sequence reads above 410,000 did not provide any greater level of detection 
[60].  Several months following the publication of the DANSR model, Sparks et al. published the 
FORTE model for optimized detection.  The FORTE model analyses polymorphic and 
nonpolymorphic loci to optimize trisomy evaluation.  The study recruited 250 euploid 
pregnancies, 72 cases of Trisomy 21, and 16 cases of Trisomy 18 pregnancies, with aneuploidy 
status blinded from the lab.  Like the last study by Sparks et al., chromosome 18 and 21 had 
nonpolymorphic loci each, but there were an additional 192 SNP containing loci on 
chromosomes one through 12.  SNPs were used to determine fetal fraction.  All olgionucleotides 
were pooled, and run as a multiplex assay.  The FORTE algorithm estimates risks of aneuploidy 
using an odds ratio.  The major differences when using FORTE analysis are that 96 samples in a 
single lane can be analyzed using the observed variance within and between samples rather than 
estimating variance upon information from a previously analyzed data set.  FORTE also 
responds to fetal fraction for euploid and aneuploid cases, and it incorporates age-related risks 
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for aneuploidy. All cases of fetal Trisomy 21 and 18 were correctly identified using these 
methods [61].   
Ashoor et al. studied the detection of Trisomy 21 and 18 by chromosome-selective 
sequencing of cell free fetal DNA during the first trimester.  Samples were obtained from 300 
euploid pregnancies, 50 pregnancies with Trisomy 21, and 50 pregnancies with Trisomy 18, at 
gestational age 11-13 weeks, prior to having CVS.  Trisomy 21 detection sensitivity was 100%, 
and Trisomy 18 sensitivity was 98%, both with 100% specificity [62].  Norton et al. performed a 
large scale validation study, deemed the Non-Invasive Chromosome Evaluation (NICE) study.  
The validation study collected 81 cases of Trisomy 21, 38 cases of Trisomy 18, 2888 “normal” 
cases and 73 “other” samples from three countries.  The study determined Trisomy 21 sensitivity 
to be 100%, with specificity of 99.9%, and for Trisomy 18 a sensitivity of 97%, with 99.9% 
specificity.  The testing had a 4.6% failure rate, where the fetal DNA concentration was too low, 
or the assay did not work properly.  The study determined that fetal fraction did not vary with 
subject’s race, ethnicity, maternal age, or trisomy type, or gestation age between 10-22 weeks 
[63].  Studies were completed by Ashoor et al. and Brar et al. regarding factors that influence 
fetal fraction of cell-free DNA in maternal plasma.  Brar studied the concentration of cell-free 
fetal DNA in maternal plasma in relation to the a priori risk for fetal trisomy, as used in the 
FORTE method to determine baseline risk evaluation.  The study determined that there is no 
statistically significant association between fetal karyotype, crown-rump length, NT 
measurement, screening results, or maternal characteristics and the concentration of cell free 
fetal DNA in circulation [64].  Ashoor et al. studied the concentration of cell-free fetal DNA in 
maternal plasma at 11-13 weeks gestational age in relation to maternal and fetal characteristics.  
Approximately 2000 pregnant women were recruited for the study that were between 11 and 13 
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weeks gestational age.  They found that fetal fraction decreases with increased maternal weight 
and Afro-Caribbean racial origin, and increases with increased levels of hCG and PAPP-A, and 
with increased fetal crown-rump length, fetal Trisomy 21, and maternal smoking [65].  These 
associations with cell-free fetal DNA concentration may be important factors when statistically 
correcting for sample variability. 
 Harmony currently does not require a high risk pregnancy classification in order to 
perform NIPT, and they do not offer sex chromosome aneuploidy testing. The detection rates for 
clinical NIPT through Harmony are listed below: 
Table 4. Ariosa's Harmony Testing 
Chromosome 
Aneuploidy 
Detection Rate False Positive Rate 
Trisomy 21 >99% (214/214) <0.1% 
Trisomy 18 >98% (103/105) <0.1% 
Trisomy 13 80% (8/10) <0.1% 
Adapted from Ariosa’s website [66] 
 
 The final laboratory offering NIPT is Natera, whose test is named Panorama.  The proof 
of concept study was published in 2012, which included 166 samples (11 Trisomy 21, three 
Trisomy 18, two Trisomy 13, two 45,X, and two 47,XXY).  Most aneuploidy samples were 
drawn after invasive testing, and karyotype results were not blinded by laboratory researchers.  
The method described, called Parental Support, requires parental genotypes, data from the 
Hapmap Database, and the number of sequence reads associated with the relevant alleles at 
11,000 SNP loci.  The data are used to create billions of possible monosomic, disomic, and 
trisomic fetal genotypes at these loci, and Bayesian statistics are used to determine the relatively 
likelihood of each hypothesis.  Probability distributions are calculated for the observed allele 
distributions compared to expected allele distributions to determine the most likely scenario.  
Statistical calculations are completed by the NATUS statistical algorithm.  A data quality test is 
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also performed to assess DNA quality.  In this study, 21 samples did not pass the DNA quality 
test (12.6%), and sensitivity and specificity for all euploid and aneuploid samples was 100% 
[67].  They currently are not requiring high risk pregnancy classification, and will collect 
samples as early as nine weeks gestational age. 
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3.0  MATERIALS AND METHODS 
3.1 DATA COLLECTION 
3.1.1 Patient Population 
Patient recruitment occurred at Magee-Womens Hospital in Pittsburgh, Pennsylvania.  The 
patient population was composed of pregnant women over the age of 18, who were between 10 
and 22 weeks gestation.  Patients were given the opportunity to participate in the research if they 
were considered among the “high risk” pregnancy population.  The definition of “high risk” 
population includes advanced maternal age, abnormal serum screen result, personal or family 
history of genetic condition, and/or abnormal ultrasound [68].  Patients were undergoing routine 
first trimester screening, or electing prenatal diagnosis by CVS or amniocentesis.  Several “low 
risk” pregnancies were also recruited by inviting patients who were scheduled for routine first 
trimester screening and did not meet “high risk” pregnancy criteria.  This pool of “low risk” 
patients served as negative controls [69]. 
3.1.2 Participant Recruitment and Informed Consent 
All patients who elected to participate in the research study were recruited and gave informed 
consent at the Center for Medical Genetics at Magee-Womens Hospital in Pittsburgh, 
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Pennsylvania under IRB protocol number PRO07090033.  Recruitment was accomplished by 
genetic counselors and genetic counseling interns during genetic counseling appointments or 
during brief consults.  Patients who were eligible to participate in this research were selected 
from genetic counseling and first trimester screening schedules, available on Magee’s Genetic 
Information System (GIS).   
Information regarding research participation was provided and informed consent was 
obtained at the end of genetic counseling sessions, prior to first trimester screening or prenatal 
diagnostic procedures.  For patients not participating in genetic counseling sessions, genetic 
counseling interns (employed as a patient recruiter by the research laboratory) met with patients 
to provide information and obtain informed consent prior to blood collection for first trimester 
screening. 
Informed consent consisted of a discussion of research study background, specific aims, 
participation requirements, risks of participation, rights of the participant, and sample handling.  
Patients were given the opportunity to review the consent form (Appendix A), discuss questions 
and concerns, and provide signature, printed name, and date on the last page of the consent form.  
Genetic counselors or genetic counseling interns, who served as recruiters, completed the last 
page of the consent form by providing their signature, printed name, and date.  The completed 
consent form was copied and retained in the patient’s chart at Magee-Womens Hospital.  The 
original completed consent form is filed in a locked cabinet at the research laboratory.  No 
samples were obtained without the consent of a patient. 
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3.1.3 Sample Collection and Tracking 
After providing informed consent, and completing consent paperwork, research participants were 
given a prescription for blood work.  The phlebotomy lab at Magee-Womens Hospital obtained 
approximately 36 milliliters of blood from each patient (six purple top tubes).  Blood samples 
were collected and transported to the research lab within two hours of blood draw for processing. 
Sample collection and transportation to the research lab were documented in the patients 
GIS entry in the Reference Lab tab.  All samples were de-identified upon entering the lab.  A bar 
code was given to each sample, which was used to track the blood sample, DNA, sequencing 
library, and results.  The bar code also provides patient clinical and demographic information, 
which includes prenatal diagnostic test results and pregnancy and birth outcome. 
3.2 SAMPLE PROCESSING 
3.2.1 Separation of Plasma from Whole Blood 
Whole blood was centrifuged for 13 minutes at 1600xg at 4ºC, with acceleration and deceleration 
set to 3.  Aliquots of 1 ml of plasma were pipetted into 1.5 ml microcentrifuge tubes and spun at 
16000xg for 10 minutes at 4ºC to form a pellet.  900 µL of suspension from each tube were 
transferred to a clean 1.5 ml microcentrifuge tube.  Plasma aliquots were stored at -80ºC [69]. 
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3.2.2 DNA Extraction from Plasma 
Plasma samples were used to extract DNA using the QIAamp DNA Blood Mini Kit and 
specified reagents.  One frozen plasma sample was thawed to room temperature and divided into 
two tubes.  40 µL of Qiagen Protease was added to each tube and mixed by inverting the tube 
five times.  400 µL of Buffer AL was added to each tube, and the sample was mixed by 
vortexing for 15 seconds.  Samples were incubated at 56ºC for 10 minutes.  400 µL of 100% 
ethanol was added to each tube and tubes were mixed by vortexing for 15 seconds.  600 µL of 
the mixture was applied to the spin column and spun at 6000xg for one minute.  Elution of the 
sample may be repeated in order to pass the entire plasma sample through the column.  The 
column was washed by adding 500 µL Buffer AW1 and spun for 1 minute at 6000xg.  500 µl of 
Buffer AW2 was added to the column and centrifuged at max speed for 3 minutes.  Residual 
ethanol was removed by placing the column in a clean collection tube and centrifuging for 1 
minute at maximum speed.  To elute the DNA, the column was placed in a 1.5 mL tube and 75 
µL of RNase/DNase free water was added to the column.  The column was incubated at room 
temperature for 5 minutes and then centrifuged for 1 minute at 6000xg. 
3.2.3 Real Time PCR Analysis of SRY and Bglobin  
Primers and probe sequences for the real time PCR reaction were obtained from Maron, et al. 
SRY: Forward primer 5’ – TCCTCAAAAGAAACCGTGCAT – 3’; Reverse primer 5’ – 
AGATTAATGGTTGCTAAGGACTGGAT – 3’; Probe 5’ – FAM – 
CACCAGCAGTAACTCCCCACAACCTCTTT – TAMRA – 3’.  
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B-globin: Forward primer 5’– GTGCACCTGACTCCTGAGGAGA – 3’; Reverse primer 
5’ – CCTTGATACCAACCTGCCCAG – 3’; Probe 5’ – FAM – 
AAGGTGAACGTCCATGAAGTTGGTGG – TAMRA – 3’. 
B-globin is a ubiquitous housekeeping gene and was run concurrently with SRY to 
ensure that DNA was present in each sample, irrespective of fetal gender. In order to estimate 
DNA concentration in the plasma DNA, standard curve DNA was run simultaneously with the 
plasma DNA. The standard curve DNA was prepared using commercially available DNA with 
known concentrations. The range of values for the standard curve was 6.4 pg/5 µL to 20,000 
pg/5 µL. Each real time PCR reaction consisted of: 12.5 µL 2x TaqMan Universal PCR Master 
Mix, 1.25 µL 10 µM forward primer, 1.25 µL 10 µM reverse primer, and 0.0625 µL 100 µM 
probe. 10 µL plasma DNA, 5 µL standards, or 10 µL water (to serve as a negative control) were 
added to the appropriate wells. Each plasma DNA sample and the negative control were run in 
triplicate. The standard curve DNA was run in duplicate. The thermal cycling conditions were 
initial denaturation step of 95°C for 10 min, followed by 50 cycles of 95°C for 15 sec and 60°C 
for 1 min. The real time PCR reactions were done using the 7900HT Sequence Detection [69]. 
3.2.4 System (Applied Biosystems).Plasma Sequencing 
Plasma sequencing used the Illumina Truseq DNA sample prep kit, minus the gel purification 
step.  The following oligos 5’-ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TC*T-3’ 
and 5’-/5Phos/GAT CGG AAG AGC TCG TAT GCC GTC TTC TGC TTG – 3’ were 
resuspended in TE and annealed in 1X T4 DNA Ligase Reaction Buffer (NEB) by heating at 
95ºC for 5 minutes and then slowly cooled to room temperature for a final concentration of 36 
µM annealed adaptor.  Plasma DNA fragments were end repaired and then terminal A-residues 
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were added using the NEBNext End Repair and the NEBNext dA-tailing modules as per 
manufacturer’s protocols.  Following reaction cleanup using the MinElute Cleanup kit (Qiagen), 
DNA fragments were combined with 0.05 µM adaptor and 400U T4 DNA ligase (NEB) and 
incubated for 1 hour at 16ºC.  After reaction cleanup with MinElute Cleanup kit, PCR was 
performed using the following primers: 5’- CAA GCA GAA GAC GGC ATA CGA GCT CTT 
CCG ATC*T -3’ and 5’-AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC 
CTA CAC GAC GCT CTT CCG ATC*T -3’ and Phusion High-Fidelity DNA polymerase.  PCR 
conditions were an initial denaturation (98ºC, 30s), 30 cycles of 98ºC for 10s, 65ºC for 30s, and 
72ºC for 30s, with a final extension of 72ºC for 7 min.  Following amplification, the PCR 
reaction was cleaned up using the MinElute PCR Purification kit (Qiagen) [69]. 
3.2.5 Preparation of Targeted Sequencing Libraries 
Standard Illumina TruSeq protocols were used to create plasma DNA libraries.  A 15 cycle PCR 
reaction was performed and 500 ng of the resulting product incubated Agilent with SureSelect 
biotinylated probes for 24 hours, according to the manufacturer’s instructions.  Baits spanning a 
region between chr12:22,455,568-30,651,389 (hg19) were designed for this purpose by Agilent.  
Targets were captured using Dynal MyOne Streptaviden T1 beads (Invitrogen) and a final library 
amplification of 12 cycles was carried out as described in the Illumina TruSeq protocol.  
Libraries were quantified using real time PCR and sequenced on a HiSeq2000 (Illumina) using 
100bp paired-end reads[70]. 
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3.2.6 Array Based Comparative Genomic Hybridization 
Array based comparative genomic hybridization (aCGH) was performed using whole-genome 
135K (SignatureChip Oligo Solution version 2.0, custom designed by Signature Genomic 
Laboratories, manufactured by Roche NimbleGen, Madison, WI, USA).  Results were visualized 
using custom aCGH analysis software (Genoglyphix; Signature Genomic Laboratories).  Fetal 
DNA was isolated from cultured amniocytes using PureGene DNA kit (Gentra) and tested for 
maternal cell contamination.  Fetal DNA and normal male control DNA were differentially 
labeled with cyanine 3-dCTP and cyanine 5-dCTP (Perkin Elmer) using BioPrime labeling kit 
(Invitrogen), and hybridized onto an oligonucleotide array for 24 hours.  Metaphase FISH 
analysis using 12p11.23 specific probe were performed on cultured amniocytes and in PHA 
stimulated peripheral blood samples obtained from the fetus and both parents [70]. 
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4.0  CHROMOSOME 12 MICRODELETION 
The following describes the proof on concept that was recently demonstrated for the detection of 
a 4.2 Mb deletion on chromosome 12 using NIPT. 
A family presented to Magee-Womens Hospital of UPMC at the Medical Genetics 
department in 2011 due to a previous child with a 4.2 MB deletion on 12p12.1-p11.22. 
 
Figure 1.  Chromosome 12 Pedigree 
  The previous child was born at 37 weeks gestational age, weighed five pounds, nine 
ounces, and was 17.25 inches long.  She was seen by the Genetics department at Children’s 
 35 
Hospital of Pittsburgh for dysmorphic facial features, failure to thrive, developmental delay, and 
low muscle tone at ten months of age.  Testing was completed which revealed the deletion 
containing 16 OMIM genes.  This deletion was determined to be paternally inherited.  Genetic 
testing was performed for Prader-Willi syndrome and Fragile-X, which were negative. Metabolic 
and thyroid studies were within normal limits. 
The family was expecting a second child, and came to the department for prenatal genetic 
counseling and testing.  The mother was Gravida three, Para one, and had an amniocentesis at 21 
weeks gestational age.  A karyotype showed a normal male (46,XY).  Array-CGH was 
performed on DNA extracted from the amniotic sample, and a single-copy loss of 12p12.1-
p11.22, was detected and confirmed by FISH analysis.  Microarray analysis also detected copy 
number changes on chromosomes 1q31.1 (161.6KB loss), 8p11.23 (92.1KB loss), and Xp22.33 
(101.9KB gain).  The child was delivered weighing five pounds, ten ounces, and was 18.5 inches 
long.  The child has also been seen by Children’s Hospital of Pittsburgh, Genetics department for 
failure to thrive and growth delays. 
4.1 METHODS 
Fetal genome equivalents from the maternal blood plasma sample were calculated as 5.7% by 
real time PCR.  Plasma DNA was used as a substrate for single end read (35bp) Illumina DNA 
sequencing, which generated 243,340,714 reads.  Of these reads, 75% could be mapped uniquely 
and perfectly to the latest version of human reference genome GRCh37.  We selected 22 non-
overlapping regions; about 4 million base pairs each, from the reference genome.  Twenty of the 
regions were from chromosome 14 and two from chromosome 12.  The two regions of 
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chromosome 12 chosen included the region of the deletion, and the region immediately upstream 
of the deletion.  GC content and read density were calculated for each region.  Read density is 
the median number of reads aligned to a moving window of width 50000bp in that region.  Seven 
maternal plasma libraries were obtained which had both maternal and fetal diploid chromosomes 
12 and 14, as reference libraries.  The statistical methods used for this analysis have been 
previously published [70, 71].    
4.2 RESULTS 
The deletion sample was compared to these reference libraries using the 22 test regions to 
determine if the 12p deletion’s region was diploid.  The p-values were adjusted for family-wise 
error using Holm’s method.  In all seven comparisons, detection of a single copy fetal loss of the 
12p region was determined in DNA from maternal plasma.  No false positives were reported for 
the other 21 regions [70]. 
Whole genome DNA sequencing of maternal plasma DNA has potential for NIPT of fetal 
microdeletions and/or microduplications.  One advantage to this approach is that such genomic 
changes can be detected without prior knowledge of the mutation or locus of interest.   Due to 
the large amounts of sequence data required, and the cost of whole-genome next-generation 
sequencing procedure, it may be less likely to be implemented clinically.  One way to reduce the 
amount of sequencing data required, thus reducing costs, would be to use genome capture and 
targeted sequencing. 
The maternal plasma sample with a fetal 4.2Mb microdeletion, as described above, with 
three normal pregnancy maternal plasma samples, were subjected to targeted region capture of 
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an 8Mb sequence on chromosome 12p12.1-p11.22 followed by next generation DNA 
sequencing.  The sample with the deletion (aka PL565) had approximately 45 million paired 
sequence reads, of which, 40 million could be aligned to the reference genome.  The 8Mb 
sequence was divided into 19 non-overlapping regions of 400Kb each.  Ten of these regions are 
located in the deleted region of interest, and nine lie outside the region and were used as 
references.  For the PL565 sample, 1.3-1.9 million reads for completed for each region.  The 
GCREM algorithm was used to test the PL565 library against three normal libraries.  Significant 
p values were obtained for the ten regions in the deleted region of interest, and non-significant p 
values were obtained for the nine regions outside of the deleted region, suggesting that the 
targeted capture method with GCREM is capable of detecting deletions as small as 400Kb.  The 
same result was obtained when testing a quarter of the PL565 library with GCREM, suggesting 
that about 300,000 reads per region is sufficient to detect fetal deletions and duplications in that 
region from a maternal plasma sample [70, 72].  See figure three for data analysis. 
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5.0  CHROMOSOME 5 MICRODELETION 
The following describes the detection of a 319 Kb subtelomeric deletion using NIPT.  A family 
presented to Magee-Womens Hospital of UPMC at the Medical Genetics department.  The 
mother was Gravida eight, Para three, and was seen at 19.0 weeks gestational age due to an 
increased risk for Down syndrome (1:42) and open neural tube defect (1:160) by multiple marker 
screen.   
 
Figure 2.  Chromosome 5 Pedigree 
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An amniocentesis was performed, and during ultrasound for the procedure, bilateral club 
feet and an echogenic bowel were noted.  Karyotype and FISH analysis from the amniocentesis 
revealed 46,XX.  Microarray analysis revealed a 318.46kb loss of 5p15.33; a variant of uncertain 
significance, whose region includes five OMIM genes.  Cri-du-chat syndrome is found in the 
deleted region, but the critical region was not included.  FISH studies determined the deletion 
was of paternal origin.  The patient was recruited for the study during a follow up prenatal 
appointment.  The child was born at 39 weeks gestational age, weighed four pounds, 12 ounces, 
with a length of 43 cm.  She was seen by the Genetics department at Children’s Hospital of 
Pittsburgh following reports of developmental delay, hypotonia, polymicrogyria and bilateral 
posterior white matter loss with distortion of the lateral ventricles on MRI, farsightedness, and 
some hearing loss.  Physical exam during that consultation revealed Brushfield spots, and height, 
weight, and head circumference in the seventh percentile for growth.  Due to the polymicrogyria, 
genetic testing for GPR56 was pursued, and results are currently pending. 
Currently the couple is pregnant, and came in for prenatal counseling and CVS at 11 
weeks, one day gestational age, where mother and father were re-recruited for the research study, 
with the anticipation of sample collection from CVS, and correlation with FISH, Karyotype, and 
microarray testing results. 
5.1 METHODS 
The samples were statistically analyzed using the MINK derivative, GCREM, as previously 
published [70, 71]. 
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5.2 RESULTS 
Appendix two contains the analysis of the samples used to detect the fetal microdeletion.  Figure 
four shows the analysis of the chromosome five region of interest with the DNA from maternal 
whole blood compared against plasma DNA control libraries.  Figure five shows the analysis of 
the same region with DNA from maternal whole blood compared against placental DNA from 
CVS control libraries.  Changing the control libraries altered the number and degree of outliers, 
with CVS control libraries providing a more precise data output.  The result is unexpected, as a 
whole blood sample should be best controlled by another blood sample library, rather than 
placental tissue.  Since we know the fetal microdeletion is paternally inherited, we do not expect 
to find any copy number variants in the region in the maternal sample.   
Figure six shows the fetal sample from CVS/amniocentesis with the plasma DNA control 
library.  Figure seven shows the fetal sample from CVS/amniocentesis with the control library of 
DNA from CVS.  In both figures, the microdeletion is well visualized within the outlined region 
between 227979 and 530932.  There is less variability in the amount of loss represented when 
using the CVS DNA control library. 
Figure eight represents the analysis of cell free fetal DNA from maternal plasma with a 
plasma DNA control library.  Figure nine shows the same sample with placental (CVS) DNA 
control library.  Both control libraries allow for the detection of the microdeletion, but the 
placental DNA control show less variation surrounding the deletion, and neither cell free fetal 
DNA sample shows the microdeletion as clearly as the amniocentesis sample. 
Several questions are raised based on the difference in results observed by using plasma 
and CVS DNA control libraries.  First, there are discrepancies in our records regarding the type 
of sample collected for analysis: either CVS or amniocytes, and if either was successfully 
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obtained.  Secondly, would the sample type (amniocenteisis) discrepancy with the control library 
(CVS) significantly change the results?  Depending on the sample collected, the control library 
used (CVS) may be inappropriate.  Also, are there major differences in DNA sequence, 
variability, GC content, or other epigenetic factors between plasma and placental tissue DNA?  
Would these possible variations explain the differences in results, and are there ways to account 
for these variations in future studies?  Next, are the other gains and losses noted by analysis true 
gains and losses, or are they artifacts of the procedure?  This region on chromosome five does 
not currently have quality coverage by microarray probes.  This lack of coverage may be due to 
highly repetitive sequences within this region, which lead to bias in analysis.  Would this 
sufficiently explain the great variation observed in our analysis, or may there be other 
explanations?  The variability in the results warrants further investigation.  Laboratory 
techniques, analysis, and statistical methodologies may need to be improved in order to more 
accurately detect this type of microdeletion.  Based on these results, expanding NIPT to detect 
microdeletions and microduplications in the clinical setting must be delayed until results can 
more accurately and reliably be determined. 
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6.0  DISCUSSION 
6.1 PUBLIC HEALTH IMPLICATIONS 
We demonstrated that some microdeletions can be accurately detected using NIPT, which 
implies the potential expansion of this technology in both research and clinical applications.  
Fetal microdeletions and duplications are currently detected by microarray analysis using 
invasive methods, including CVS and amniocentesis.  Development of a non-invasive test to 
detect these small genetic changes has significant public health implications.  It would provide a 
safe, non-invasive option, and with greater sensitivity and specificity than current screening 
options, potentially replacing current pregnancy screening options.  The detection of aneuploidy 
using NIPT has impacted public health in the prenatal setting among high risk pregnancies, and 
further impacts will be made as technology improves. 
High risk pregnancies could be reclassified following a negative result when testing for 
aneuploidy, microdeletions, and microduplications.  Reclassifying pregnancies decreases patient 
anxiety, reduces unnecessary exposure to further screening and testing, and can limit invasive 
procedures and the associated risks of miscarriage.  Saving patients the anxiety and time 
associated with current pregnancy screening options has the ability to save physicians time, but 
may cost hospitals and insurance companies’ more money by consolidating routine screening 
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and testing procedures into one test.  Implementation of NIPT in routine prenatal care has 
implications for reproductive and public health policies, not just in the United State, but globally.   
This research describes technology that could be offered world-wide in an effort to 
improve the prenatal care of women.  The NIPT technology could be useful in hospitals and 
medical practices that do not regularly perform invasive procedures.  Centers with fewer 
procedures often have higher rates of complications, miscarriage, and preterm labor following 
CVS or amniocentesis, and NIPT could serve as a virtually risk-free alternative.  Providing 
women and families with an option to gain information about their pregnancy empowers them, 
and provides reproductive autonomy and the ability to make informed decisions about pregnancy 
management.  As technology improves and costs decrease, NIPT could be applied globally to aid 
in the detection of aneuploidy and other chromosomal alterations in pregnancy. 
6.2 FUTURE DIRECTIONS OF THIS RESEARCH 
The data and methodology presented in this paper provide a foundation for ongoing and future 
research by this group.  As more samples are recruited for this study, validation studies for the 
detection of aneuploidy, microdeletions, microduplications, and other chromosomal alterations 
can be completed.  These validation studies will help to identify and improve testing specificity 
and sensitivity.  With the development and improvement of novel statistical analysis, our testing 
will provide greater predictive powers than first trimester screening for fetal aneuploidy.  For the 
detection of microdeletions, NIPT may be a method to obtain results similar to microarray 
analysis.  Validation studies of NIPT can determine if the levels of sensitivity and specificity of 
microarray analysis can be reached.  Further studies should be completed to determine the 
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molecular differences between DNA samples derived from plasma and placenta.  Differences 
between the two sources may have implications for analysis and statistical corrections.   
Our research group hopes to expand the use of NIPT for detection of other fetal genetic 
conditions, including monogenic diseases.  Other research applications of this technology may 
include paternity testing and carrier testing for the fetus.  Our research group also continues to 
study the statistical analysis of samples in hopes to improve detection of genetic changes, and to 
correct for samples specific variability.  As we continue to improve our methodology, it is 
possible that our group may be able to offer NIPT within Magee-Womens Hospital, thus 
reducing costs of shipping samples elsewhere, and providing revenue to the hospital.   
6.3 TECHNICAL CONSIDERATIONS OF NON-INVASIVE PRENATAL TESTING 
Non-invasive prenatal testing has expanded recently, and is offered clinically by several 
companies.  Improvements are vital for the growth of NIPT, including more universal fetal 
specific markers, stronger statistical analysis, and molecular studies of sample differences.   
The first area of technological improvement is the differentiation of fetal DNA from 
background maternal DNA by developing a universal fetal specific marker.  Previous studies 
have used methylation specific and SNP specific markers to distinguish fetal DNA from 
maternal DNA.  One disadvantage of using methylation specific markers is that the protocol used 
to differentiate methylation status may damage DNA, and make detection of small genomic 
alterations more challenging due to the degradation of the sample.  SNP specific markers may 
not be advantageous due to the population and ethnic variances.  Finding universal SNPs, to 
apply to all geographic populations would be advantageous for the distribution of this 
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technology.  A universal marker that distinguishes fetal DNA from maternal DNA that is gender 
independent, widely applicable among diverse populations, and can be reliably detected without 
impacting DNA structure and integrity, is crucial for the improvement of NIPT.   
The next area of technological improvement is the statistical correction for sample 
variation.  Previous studies have found that GC content differs among each chromosome, and 
that very high or low GC content makes detection of genetic imbalances more difficult [49].  
Appropriate statistical correction for this variation will improve testing specificity and 
sensitivity, and will make detection of a greater variety of genomic changes possible.  Greater 
correction for individual variation between samples should be studied further to help optimize 
detection. 
Finally, cell free fetal DNA was determined to originate from apoptotic cells associated 
with placental trophoblast cells, which are released into maternal circulation [28].  There are two 
considerations based on the source of DNA: first, the potential epigenetic changes to the fetal 
DNA due to the apoptotic process, and secondly the effects of confined placental mosaicism.  
First, further research must be completed on the differences in fetal DNA versus placental tissue, 
and the differences between healthy placental tissue and apoptotic placental tissue.  Trophoblast 
cells rapidly divide to create the placenta, and they assist in the transportation of nutrients to the 
fetus.  These biological roles and the potential for rapid growth and cell division of this tissue 
may have inherently different properties from other cellular DNA in the body.  Epigenetic, 
structural, and chemical changes may occur in apoptotic tissue that have not been investigated 
thoroughly, and may impact the detection and reliable report of fetal genetic status.  Secondly, 
confined placental mosaicism occurs in 1-3% of pregnancies [28].  Mosaicism is a concern when 
CVS is performed, as the tissue sample collected may be genetically different from the fetus.  If 
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the cell-free fetal DNA analyzed originates from placental tissue that has a mosaic genetic 
abnormality, a false positive report may be generated, or the analysis of maternal plasma may 
give an intermediate representation of aneuploidy—thus resulting in an unreportable or 
ambiguous result.  Further studies of confined placental mosaicism’s effect on NIPT results must 
be completed to assure accurate results, specificity, and sensitivity. 
6.4 ETHICAL CONSIDERATIONS OF NON-INVASIVE PRENATAL TESTING 
6.4.1 Target Population 
A current debate among many medical centers is: who is the most appropriate patient population 
for clinical use of NIPT, and when is the best time to offer testing?  Currently, NIPT is 
recommended for women who are considered “high risk.”  The high risk category includes 
pregnancies of advanced maternal age, abnormal serum screen, personal or family history of 
aneuploidy, and/or abnormal ultrasound.  The laboratories recommend the high risk patient 
population because they are the population used in validation studies.   
ACOG stated that screening or invasive testing of pregnancy (CVS, amniocentesis) for 
fetal aneuploidy should be offered to women of any age, which is one source of debate.  If NIPT 
expands beyond the detection of aneuploidy, would ACOG’s statement apply?  One 
contraindication for widespread use of NIPT is that is not considered a “standard of care” 
practice.  Microdeletions and microduplications are not associated with maternal age, thus 
detection could occur in any age group.  These genomic changes can occur sporadically, 
representing de novo changes, which may not be detected using traditional screening and testing 
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modalities.  Would recommendations for expanded use of NIPT reflect the new policies and 
guidelines for prenatal use of microarray analysis?  Clinicians in the obstetrical and genetic 
counseling fields must consider the current and future standard of care.   
The standard of care is shaped by the medical and legal needs of patients and physicians.  
Historically, prenatal screening and testing have become “standard of care” options after review 
of literature, professional meetings, peer discussion, and the threat of liability [22].  If a 
microdeletion, duplication, or aneuploidy could have been detected prenatally, in a non-invasive, 
risk free form, would physicians and counselors be held liable if the test was not offered?  If 
NIPT has higher specificity, sensitivity, and safety than other current options, should it be 
included as a standard of care option for pregnancies?  Until further validations studies are 
performed on a wider population of pregnancies, NIPT is not expected to become standard of 
care for low risk pregnancies. 
6.4.2 Result Reporting 
NIPT’s introduction has raised several ethical concerns including management of incidental 
findings, sex determination, findings that are unreportable or have unclear clinical significance, 
and detection of non paternity.  Incidental findings and findings of unclear clinical significance 
are particularly relevant with potential improvements in technology that rival microarray 
analysis. 
Incidental findings are identified genomic changes that were not described in the initial 
indication for testing.  Incidental findings may include mutations that predispose to adult-onset 
conditions, conditions not explained by phenotype, and genetic changes that are associated with 
conditions not originally intended to be detected (findings other than trisomy when testing for 
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trisomy conditions).  These findings may not be appropriate for the direction of care and decision 
making of a pregnancy.  Typically, children are not offered genetic testing for adult-onset 
conditions so they can exercise their own autonomy in decision making as adults.  Some have 
recommended limiting testing to well-defined genetic conditions, such as Trisomy 21, 13, and 
18, which allow for greater patient education and informed consent, and decreases the possibility 
for the detection of incidental findings.  Others argue that narrowing the scope of testing 
withholds potentially significant information and limits patient autonomy [6].  With the potential 
for NIPT to detect microdeletions, duplications, and other copy number variants, the scope of 
detection must be carefully defined.  Increased scope is considered more ethically problematic 
for several reasons, including the impossibility of creating a list of conditions “worthy” of 
detection, variable expression of conditions, changes in treatment and information, and different 
perceptions of the severity of diseases [6].  Regardless of testing scope, informed consent must 
accurately describe the type of conditions potentially detected by NIPT. 
Fetal sex determination is the second ethical concern.  Detection of sex chromosomes and 
sex chromosome aneuploidy is offered clinically.  The benefits of studying sex chromosomes in 
pregnancy are the detection of fetuses that may be affected by X-linked conditions, and sex 
chromosome aneuploidy syndromes such as Turner and Klinefelter syndromes.  The perceived 
disadvantage of sex chromosome detection is fetal sex selection.  Sex selection may occur when 
individuals want to “balance” their family, or for ethnic and cultural preferences for male or 
female children.  Determining fetal sex by NIPT is considered a non-medical use of the 
technology, therefore the indication for testing is considered informational only [73].  Non-
medical uses of screening or testing a pregnancy are typically not recommended or endorsed by 
medical professionals.  While termination of a pregnancy for the sole reason of sex selection is 
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unlawful, and majority of physicians do not support such procedures, women are not required to 
give their reasons for seeking an abortion, thus fetal sex selection cannot be completely 
eradicated [74, 75].  Caution must be exercised when using NIPT for fetal sex determination.  
Emphasis must be placed on the indication for testing (aneuploidy), rather than associated 
findings, like fetal sex. 
Unreportable results and detection of variants of uncertain clinical significance are 
concerns of NIPT expansion.  Unreportable results occur when samples are of poor quality, have 
fetal fraction too low to utilize, or if there are lab errors or uncertain results.  Improvements to 
technology may reduce the frequency of unreportable results.  As NIPT improves to rival the 
level of detection of microarray, further information regarding uncertain variants must be 
obtained.  For example, if a microdeletion was detected using NIPT which had unknown clinical 
significance, how would the pregnancy be managed?  Without phenotypic correlations, it is more 
difficult to determine the role of the genetic change on development.  Results of uncertain 
clinical significance place a greater burden upon the family, as decisions to terminate or continue 
the pregnancy are based on vague and untested information.  Some women may feel guilt and 
worry regardless of their decisions to continue or terminate the pregnancy following the 
disclosure of test results [75].  A study was completed to assess women’s reactions when 
receiving a positive result from prenatal microarray testing.  Of the 23 women interviewed, most 
reported feeling that microarray testing was an offer too good to refuse since they were already 
undergoing invasive prenatal testing, and less was understood about the possible test results. 
When a copy number variant was reported, women felt blindsided, since normal FISH 
and karyotype results were disclosed first.  Other emotions included feeling overwhelmed, 
anxious, confused, and shocked.  Confusion was reported when women received conflicting 
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information from counselors and physicians, which made pregnancy decision making more 
difficult.  Women who had ultrasounds that revealed abnormalities tended to be less shocked by 
abnormal microarray results, which justified the findings, and pregnancy termination decisions.  
Many women considered abnormal microarray results “toxic knowledge,” and wished they had 
not received the results.  Bonding with the baby was impacted, as women continued to worry 
about their child’s development, especially in cases of uncertain clinical significant findings.  
The study recommended that genetic counselors focus on social and moral values of patients, 
include discussion of the implications of positive test results prior to consent to testing, and 
continue to provide support after result disclosure [76].  Similar outcomes may occur in patients 
choosing NIPT, especially if the technology is capable of detecting small copy number 
variations.  The concerns regarding variants of uncertain significance may be limited by reducing 
the scope of testing, as discussed above. 
Another incidental finding, non paternity, describes the situation where the father of the 
fetus is biologically different from the social father.  This can be detected when fetal DNA is 
compared to the paternal DNA.  This occasionally occurs in cases where a genetic alteration has 
been detected in the fetus or child, and the mode of inheritance is being investigated.  Requesting 
NIPT for paternity testing, like sex selection, is not considered medically indicated.   It serves 
only as information, and is not typically recommended as part of prenatal care [73].  
The ethical concerns relating to the reporting of results can be limited, or best anticipated, 
by discussing the scope and indication for testing, and by providing careful and thorough 
informed consent for NIPT prior to testing. 
 51 
6.4.3 Implications of Testing 
Due to the advantages of NIPT, more women could choose this testing over invasive procedures 
like CVS and amniocentesis.  Perceived advantages for patients include less physical discomfort 
with a blood draw than an invasive procedure, increased accuracy over current screening options, 
earlier detection of genetic alterations in pregnancy, and potential for cost savings [22].  The 
shift in screening and testing could financially impact medical institutions, which regularly make 
profit from prenatal screening and testing.  With changes to the standard of prenatal care, 
insurance companies may alter their coverage policies for NIPT, which will financially change 
the use of the testing by patients. 
Some researchers have expressed concern that increased availability of genetic testing 
like NIPT, will increased the number of abortions.  The culture surrounding individuals with 
disabilities may change if the prevalence of genetic conditions is decreased.  If the culture 
becomes less accepting of individuals with disabilities, some have proposed that there would be 
increased societal pressure on women to undergo testing and to terminate effected pregnancies, 
possibly becoming a form of “passive eugenics.”  Increased societal pressure may lead to 
routinization of testing, negatively impact informed consent, and deemphasize voluntary 
participation [22, 77, 78].  Routinization of NIPT may occur regardless of societal pressure, as it 
may be perceived as “just another blood test.”  Another possible disadvantage of including NIPT 
in routine prenatal care is the “burden of choice.”  The burden of choice is when women and 
families feel overwhelmed by the options available to them for screening and testing, and they  
feel unsure about what to do with the information once it has been disclosed [6, 73].  Some cases 
of fetal aneuploidy or other genetic conditions detected early by NIPT may have naturally 
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aborted within the first trimester, and the information gained by early testing may have been 
considered “unnecessary” and served only to induce stress over pregnancy decisions [6, 79].   
Conversely, NIPT could be beneficial for families.  Anxiety may be alleviated with a 
negative result.  Many families choose to undergo prenatal screening and testing to gain more 
information in preparation for caring for a child with a genetic condition, not just for termination 
of a pregnancy.  When termination is considered, studies have found that the earlier in pregnancy 
the decision is made, the less psychologically challenging it is for families [77].  Although 
terminations rates may increase with the use of NIPT, there are safeguards in place against this 
trend, including the ability for women to obtain an abortion without a fetal genetic diagnosis, and 
couples facing the same decisions will not always choose the same course of action [78].  Early 
detection of a genetic condition can allow families to coordinate resources, support, and to gain 
information to help care for their child.  Families are better prepared to overcome feelings of 
guilt, grief, and anxiety when prenatal testing is performed early.  Early knowledge may allow 
families to form bonds with their future children rather than perpetuate feelings of ambiguity and 
uncertainty.  Financial preparation can be an advantage for families who learn that their child is 
affected with a genetic condition.  Planning for future medical care, education, and access to 
resources is beneficial to many families.  Costs may extend beyond financial considerations, as 
the value of time spent away from family, jobs, and other children to care for a child with special 
needs, and the indirect costs of providing care, must be factored into the decision making process 
[22].  With the ability to determine the genetic status of the fetus early in pregnancy, families 
have time to consider these factors to make pregnancy decisions. 
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6.5 CLINICAL CONSIDERATIONS OF NON-INVASIVE PRENATAL TESTING 
6.5.1 Clinical Need 
There is a demonstrated need for a non-invasive option for individuals desiring information 
about the genetic status of their pregnancy.  Couples must choose between a risk-free screening 
test that increases or decreases their risks with limited accuracy, or an invasive, physically 
uncomfortable, and potentially risky procedure to determine the exact genetic status of the 
pregnancy. 
Current screening tests, offered to all pregnant women, only detect Down syndrome and 
Trisomy 18, and in the case of multiple marker screening, open neural tube defects.  The highest 
detection rates for Down syndrome are less than 90%, and results are risk estimates rather than 
diagnoses.  The current risk-free, non-invasive options for pregnant women are limited, and 
NIPT would offer a way to detect genetic conditions with higher accuracy than the current 
screening methods.   
For high-risk pregnancies, women may feel that they have limited options, and invasive 
procedures are necessary.  Anxiety has been reported in nearly all women undergoing CVS or 
amniocentesis, and was most often due to concerns about possible procedure results.  Women 
who felt ambivalent due to anxiety and fear may not be capable of giving informed consent.  The 
source of these emotions may include: conflicts between invasive genetic testing and personal 
beliefs about the pregnancy, perceived value of being an educated health care consumer, 
maternal role of protector of the fetus, religious beliefs, and intellectual values [80].  Aside from 
anxiety and fear about the procedure, results, and risks, CVS and amniocentesis may be 
uncomfortable procedures.  About 54% of patients undergoing CVS and amniocentesis described 
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them as “painful”, with techniques to reduce pain, including subfreezing needles, local 
anesthesia, and massage, found to be ineffective [81].  The anxiety, fear, and discomfort 
associated with invasive procedures outline the need for safe, non-invasive prenatal options. 
A study was completed which assessed pregnant women’s interest in NIPT as a future 
option in their pregnancy care.  Of the women interviewed, 72% showed interest in the 
technology, and 95% of women wanted to meet with a genetic counselor to discuss NIPT [82].  
Other studies have shown that women place highest value on the safety of the fetus when 
considering prenatal testing and screening options.  Women and physicians valued test safety, 
timing in pregnancy, accuracy, and the ability to learn about conditions in addition to Down 
syndrome when considering NIPT [83].  Women felt that NIPT gave them time to prepare 
mentally and physically for the possibility of an affected child, increased their sense of control 
over the pregnancy, normalized the pregnancy, enhanced the couple’s decision making abilities, 
and provided peace of mind.  Women who had NIPT preferred to be given information about the 
testing by specialists with knowledge of the testing and genetic conditions, such as genetic 
counselors, genetic nurses, or physicians [84].  Women and physicians have shown an interest in 
NIPT, but many clinical care centers are struggling to determine when and how to implement 
such technology into established schedules of prenatal screening and testing. 
To determine when and how NIPT could be optimally used, studies have been completed 
prospectively to outline options for clinicians.  First, implementation of NIPT depends on how 
the technology will be regulated in the prenatal setting.  Three models have been described, 
including the governmental regulatory model, market model, and medical model.  The 
governmental regulatory model describes a medical screening test that is required by the state or 
federal government to be offered or completed.  The market model describes testing that can be 
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sold through advertising, often directly to patients.  The physician’s role is to provide services to 
consumers depending on what the patient wants, regardless of medical consensus.  The medical 
model requires a medical indication for a test to be recommended, and the patient can choose to 
have the test completed.  This is the method physicians have historically employed for testing 
specific diseases or conditions.  The medical model also explains why prenatal determination of 
fetal sex is not performed—as this would indicate that sex or gender is a “disease,” which it is 
not [85].   
The current method of NIPT implementation is the medical model.  The medical 
indication for NIPT is the increased risk of aneuploidy in high risk pregnancies.  As NIPT 
detects genetic alterations beyond aneuploidy, the medical indication would need to be altered 
appropriately.  The second most likely model for NIPT implementation is the market model.  
Other genetic testing has been offered in the direct-to-consumer setting, which poses risks to 
informed consent and proper explanation of results.  If NIPT were offered in a market model 
setting, physicians would need to be educated and equipped to explain and interpret the results 
for patients.  The market model of test implementation is not ideal, although it has potential to 
occur. 
Based on the assumption that NIPT will occur under the medical model, the next question 
is where in the sequence of prenatal care does the testing fit?  NIPT could replace current 
screening tests, be added to current screening tests, or between screening and invasive tests, or 
NIPT could replace invasive diagnostic tests [86, 87].   
If NIPT replaces current screening, therefore eliminating first trimester screening and the 
second trimester multiple marker screening, there would be defined advantages and 
disadvantages.  The first advantage is that NIPT could be completed earlier than traditional first 
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trimester screening at 10 weeks gestation.  Earlier results would give women and families time to 
make decisions about their pregnancy management and care, and would give sufficient time to 
make decisions regarding invasive testing.  Detection of aneuploidy and other chromosome 
abnormalities by NIPT would provide more information than the Trisomy 21 and 18 risks by 
first trimester screening, with considerably higher accuracy.  If NIPT is offered for diagnosing 
Trisomy 21, there could potentially be 84% fewer invasive procedures, and an additional 7% of 
cases would be diagnosed prenatally [79].   
The first disadvantage of replacing current screening with NIPT would be the loss of 
ultrasound imaging and nuchal translucency measurement.  By replacing current pregnancy 
screening with NIPT, there would be no initial risk assessment (aside from age related risk).  
Other disadvantages include risks of routinization of testing, information over-load in the first 
trimester, burden of choice, and inability to detect increased risk for pre-eclampsia, intrauterine 
growth retardation, and fetal abnormalities [88]. Several authors have recommended ultrasound 
imaging or nuchal translucency measurement in addition to NIPT to determine the number of 
fetuses (singleton versus multiples), and ensure correct pregnancy dating [89].  The disadvantage 
of including ultrasound or NT measurement with NIPT would be the challenge of describing 
what each component detects, why they differ, and why both tests would be completed [79].  
Since NIPT is still very new, many insurance companies do not provide coverage—and a stand-
alone ultrasound to accompany NIPT may be problematic for institutional billing.  If NIPT were 
to replace first trimester screening or multiple marker screening, would the patient population 
need to be altered, as current screening is offered to all pregnancies?  Also, AFP measurement 
during the second trimester would need to be completed independently for open neural tube 
defect detection.   
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If NIPT is added to current screening, it would be an additional “advanced screening test”  
because it has only been validated in high-risk pregnancy populations [89].  NIPT would better 
detect aneuploidy (and potentially other genomic alterations) than first trimester screening, but 
an ultrasound would be done for first trimester screening.  This method would allow for 
detection of other pregnancy complications by ultrasound.  The disadvantage is that screening 
tests would be accompanied by more advanced screening tests—thus extending the time between 
results and limiting the options of pregnancy termination and invasive procedures.  Some groups 
are concerned that offering NIPT with other pregnancy blood tests may cause it to become 
routinized, thus reducing the ability to obtain informed consent [87].  Physicians may be hesitant 
to order screening tests following other screening tests, rather than follow a positive screening 
test with a diagnostic test.  An increased risk for Down syndrome detected on a first trimester 
screen, with positive NIPT, then confirmed by amniocentesis would not save time or money 
compared to completing a first trimester screen or NIPT then an invasive procedure. 
If NIPT is added between screening and invasive testing, it would provide a more 
definitive risk to the pregnancy regarding aneuploidy following first trimester screening results.  
The advantage to adding NIPT between first trimester screening and multiple marker screening 
is the ability to determine pregnancy risk in a step-wise fashion [88]. The results could be 
confirmed by invasive tests if positive results are received.  This method works so that first 
trimester screening can help differentiate pregnancies at low risk from those at an increased risk 
for chromosomal conditions prior to offering NIPT.  This model is one of the most regularly 
used options, as it is specific to high risk populations, allows for diagnostic confirmation, and 
can be used as an option for women who do not desire invasive procedures to clarify their first 
trimester screening results.  The disadvantage to this method is similar to adding NIPT to current 
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screening, in that it does not save considerable amounts of time or money, and a screening test is 
technically followed by another, more “advanced,” screening test.   
Non-invasive prenatal testing could one day replace invasive testing, if the ability to 
detect the vast majority of chromosomal alterations is achieved.  At this point in time, the 
technology has only been validated in high-risk pregnancies for aneuploidy and sex chromosome 
detection.  Further validation studies would need to be completed to determine if diagnostic 
levels can be reached to transition from “advanced screening” to “diagnostic testing.”  The 
clinical need has been demonstrated, as a non-invasive diagnostic option would be well received 
by patients and physicians, but until the technology is more robust, NIPT should not replace 
invasive diagnostic testing. 
6.5.2 Implications for Genetic Counseling 
Genetic counselors face challenges to understand and explain complex procedures and findings 
to clinicians and patients with the introduction of any new genetic technology.  Non-invasive 
prenatal testing is no different, and the current and future challenges of incorporating the 
technology may reshape the field of prenatal genetic counseling. 
The National Society of Genetic Counselors released a statement regarding NIPT in 
2012.  They stated, “ The National Society of Genetic Counselors currently supports 
Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis (NIPT/NIPD) as an option for 
patients whose pregnancies are considered to be at an increased risk for certain chromosome 
abnormalities. NSGC urges that NIPT/NIPD only be offered in the context of informed consent, 
education, and counseling by a qualified provider, such as a certified genetic counselor.  Patients 
whose NIPT/NIPD results are abnormal, or who have other factors suggestive of a chromosome 
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abnormality, should receive genetic counseling and be given the option of standard confirmatory 
diagnostic testing” [90].  NSGC does not support NIPT in low risk pregnancies as a routine, first-
tier screening test, and NIPT should be offered with pre and post-test genetic counseling in a 
non-directive fashion [91]. 
A consideration for genetic counselors with the implementation of NIPT is cultural 
awareness and competency.  Prenatal care is deeply rooted in individual religious and cultural 
beliefs which must be respected.  The discussion of termination must be done with careful 
attention to the needs and desires of the patient.  Culture differences impact the implication of 
offering testing.  One study reported that approximately 5% of pregnancies in Japan have 
prenatal genetic screening, which is considerably less than in the United States [92].  Presenting 
the wide variety and range of prenatal screening options to individuals not accustomed to such 
care may be interpreted by the patient in ways the counselor may not anticipate.  Language 
differences may pose a challenge with the incorporation of new technology into prenatal care.  
Translation services must have an adequate understanding of the material and technology being 
discussed to accurately convey information to patients [78].  Counselors may wish to meet with 
the translator before the genetic counseling session to discuss what will be said and offered 
during the appointment, which may help to reduce misunderstandings.  With careful 
understanding and cultural sensitivity, NIPT can be performed in the genetic counseling setting. 
In clinical settings where a genetic counselor is unavailable, physicians and other 
clinicians may discuss and explain NIPT to patients.  Studies have found that physicians involve 
women minimally in the decision making process of screening for Down syndrome.  A study of 
62 obstetric health care providers determined that 85% of respondents did not report a high level 
of knowledge about NIPT, although 29% were likely to offer the testing [93, 94].  The 
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discrepancy between physician knowledge and the implementation of NIPT in the clinical setting 
raises concerns over informed consent, misinformation, and patient autonomy. 
Consent for NIPT needs to be thorough so that patients are aware of how the testing is 
performed and what information they could learn about their pregnancy.  Discussions should 
include the limitations and benefits of NIPT, what conditions are detected, accuracy and 
reliability of the test, the procedure itself and risks associated with blood collection, timing of 
results and how they will be disclosed, and if there is a specific indication for the patient to 
qualify for NIPT [78].  Patients are encouraged to consider the possible outcomes of testing—if 
the result is positive for a chromosome condition, how will it change their pregnancy 
management, delivery plans, or lifestyles following birth of the baby?  If the results are negative, 
will the family feel sufficiently comfortable with the results or will they still wish to pursue 
further testing?  Discussion of testing options must be performed without force or pressure, so 
that the patient’s decision can be made independently.  Adequate pre-test counseling is vital to 
retain patient autonomy.  Concerns arise when pre-test counseling is not performed, or is 
performed in a limited capacity.  The risk of routinization occurs when blood is collected for 
NIPT along with blood for a panel of other pregnancy tests.  In these situations, patients may not 
be aware of what is being tested for, or the implications of the results of NIPT.  As the scope of 
NIPT increases to include small genomic alterations, like microdeletions, a generic consent may 
be implemented, where testing is explained, but possible outcomes and conditions that could be 
detected, cannot be described until results are returned; similar to consent for microarray analysis 
[6].  Families often do not grasp the variety and range of conditions that may be detected, and the 
differences in severity, penetrance, and implications of a positive test result are disadvantages of 
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generic consent.  Families may realize after receiving the results that they did not want to know 
the information. 
The concerns for patient autonomy and informed consent underscore the need for genetic 
counselors in the prenatal setting, and the importance for current genetic counselors to stay 
informed and educated regarding new prenatal testing options.  The role for genetic counselors in 
the prenatal setting may shift away from discussion of less accurate screening tests, and risk-
laden invasive procedures, and focus on newer, more accurate, and safer tests for their patients. 
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APPENDIX A: CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
  
 
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
 
TITLE: Biological Analysis of Fetal Nucleic Acids in Maternal Plasma 
 
Mother’s Consent Form 
 
PRINCIPAL INVESTIGATOR:  David G. Peters, Ph.D. 
      Associate Professor 
 Department of Obstetrics, Gynecology and Reproductive Sciences 
      Magee-Womens Research Institute 
      204 Craft Avenue 
      Pittsburgh, PA 15213 
      Office: 412-641-2979 
      Fax: 412-641-6156 
 
CO-INVESTIGATORS:   W. Allen Hogge, M.D. 
      Professor and Chair 
  Department of Obstetrics, Gynecology and Reproductive Sciences 
      Director, Center for Medical Genetics 
      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213 
      Tel: 412-641-4212  
 
      Aleksander Rajkovic, M.D. 
      Associate Professor 
  Department of Obstetrics, Gynecology and Reproductive Sciences 
University of Pittsburgh  
SCHOOL OF MEDICINE 
Department of Obstetrics, Gynecology and Reproductive Sciences 
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      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213 
      Tel: 412-641-4164  
 
      Marta Kolthoff, M.D. 
      Assistant Professor  
  Department of Obstetrics, Gynecology and Reproductive Sciences 
      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213 
      Tel: 412-641-4168 
 
      Hyagriv Simhan, M.D. 
  Associate Professor  
  Department of Obstetrics, Gynecology and Reproductive Sciences 
      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213       
      412-641-4222 
   
      Stephen P Emery M.D. 
      Assistant Professor  
  Department of Obstetrics, Gynecology and Reproductive Sciences 
      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213 
      Tel: 412-641-3382 
 
 
SOURCE OF SUPPORT:   Department of Obstetrics, Gynecology and Reproductive Sciences 
 
Why is this research being done? 
It is currently very difficult to test for diseases and abnormalities during pregnancy. Two common medical 
procedures that are used to test the health of the unborn baby are chorionic villus sampling (CVS) and 
amniocentesis. Both of these procedures carry a level of risk to the baby.   
 
The study in which you are being asked to participate will explore new minimal risk methods for testing the 
health of unborn babies. These new methods use only a routine blood sample taken from the mother’s arm. This 
blood sample is obtained in exactly the same way as any other routine blood sample. We will investigate whether 
blood samples obtained in this way can be used to evaluate the genetic disorders of unborn babies. 
 
Who is being asked to take part in this research study? 
We are inviting 1950 pregnant women (>18 years old) who are undergoing either chorionic villus sampling 
or amniocentesis to participate in this research.  Also included in this study are women who are undergoing a first 
trimester blood test for fetal chromosomal abnormalities. We are also recruiting a small number (50) of partners of 
the above women so that paternal samples may also be collected in cases where a genetic anomaly in the family 
tree is known or suspected. 
 
What procedures will be performed for research purposes? 
Screening Procedures: 
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None 
 
Experimental Procedures: 
 
If you decide to take part in this research study, we will obtain a blood sample (about 8 teaspoonfuls) from a 
vein in your arm. This will require only a few minutes of your time. In addition, if you are having chorionic villus 
sampling or amniocentesis, we will save the cells that would normally be discarded afterwards and these will be 
analyzed in the same way as your blood sample in order to compare the results.  If you are not undergoing chorionic 
villus sampling or CVS we may save a very small portion of your placenta or some blood from the umbilical cord. 
These are tissues that would otherwise be discarded after birth. This testing will allow the investigators to confirm that 
their analysis from your blood is a correct one.  Approximately one month after your due date we may review your 
medical records to obtain general information about the pregnancy outcome. 
 
The samples we obtain from you may be stored for an indefinite period of time prior to experimental 
analysis.  If this is the case the sample will be stored in a freezer in the Principal Investigator’s laboratory.  This 
laboratory is in a security controlled building.  Identifiers that link your sample to your medical records will be 
removed and your sample will be encoded such that only the Principal Investigator will know the details of the code.  
The details of the code will remain in a locked filing cabinet in the Principal Investigator’s office, which itself is kept 
locked and is within a security controlled building. 
 
No information obtained in this study will directly benefit you or your unborn child. Therefore, the results of 
the testing will not be communicated to study participants. 
 
Monitoring/Follow-up Procedures: 
None 
 
What are the possible risks, side effects, and discomforts of this research study? 
The risks of this procedure are no greater than those you would experience when undergoing a routine 
blood test.  You may experience pain/discomfort from the needle insertion; slight bruising at the site, and there is a 
slight risk of infection and a very rare possibility of fainting. Because we will obtain information from your medical 
records there is a slight risk of breach of confidentiality. We will guard against this by removing any information that 
could be used to identify you and replacing this with a code. The only people with access to this code will be the 
principal investigator (Dr Peters) and co-investigators (Drs Emery, Hogge, Kolthoff, Rajkovic and Simhan). The 
details of the code will be kept in a locked filing cabinet in the principal investigators office, which is in a restricted 
access building. 
 
Although we will not directly be performing paternity tests, it is possible that we will identify rare instances 
where the mother and father have genotypes that are not consistent with the genotype of the baby. This would 
indicate non-paternity. In these instances the results will remain confidential and will not be shared with the study 
participants. 
 
What are possible benefits from taking part in this study? 
You will receive no direct benefit from taking part in this research study.  However, information learned from 
this study may contribute to better tests in the future to detect disorders of unborn babies. 
 
What treatments or procedures are available if I decide not to take part in this research study? 
The clinical treatments or procedures you undergo will not be altered in any way if you decide not to take 
part in this research study. 
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If I agree to take part in this research study, will I be told of any new risks that may be found during the 
course of the study? 
You will be promptly notified if, during the conduct of this research study, any new information develops 
which may cause you to change your mind about continuing to participate. 
 
Will my insurance provider or I be charged for the costs of any procedures performed as part of this 
research study? 
Neither you, nor your insurance provider, will be charged for the costs of any of the procedures performed 
for the purpose of this research study (i.e., the Screening Procedures, Experimental Procedures, or 
Monitoring/Follow-up Procedures described above). You will be charged, in the standard manner, for any procedures 
performed for your routine medical care. 
 
Will I be paid if I take part in this research study? 
There is no financial compensation associated with participation in this study. 
 
Who will pay if I am injured as a result of taking part in this study? 
University of Pittsburgh researchers and their associates who provide services at University of Pittsburgh 
Medical Center (UPMC) recognize the importance of your voluntary participation in their research studies. These 
individuals and their staffs will make reasonable efforts to minimize, control, and treat any injuries that may arise as a 
result of this research. If you believe that you are injured as a result of the research procedures being performed, 
please contact immediately the Principal Investigator or one of the co-investigators listed on the first page of this 
form. 
Emergency medical treatment for injuries solely and directly related to your participation in this research 
study will be provided to you by the hospitals of UPMC. It is possible that UPMC may bill your insurance provider for 
the costs of this emergency treatment, but none of these costs will be charged directly to you. If your research-related 
injury requires medical care beyond this emergency treatment, you will be responsible for the costs of this follow-up 
care unless otherwise specifically stated below. There is no plan for monetary compensation. You do not, however, 
waive any legal rights by signing this form. 
 
Who will know about my participation in this research study? 
Any information about you obtained from this research will be kept as confidential (private) as possible. All 
records related to your involvement in this research study will be stored in a locked file cabinet. Your identity on these 
records will be indicated by a case number rather than by your name, and the information linking these case numbers 
with your identity will be kept separate from the research records. You will not be identified by name in any 
publication of the research results. 
 
Will this research study involve the use or disclosure of my identifiable medical information? 
This research study will involve the recording of current and/or future identifiable medical information from 
your hospital and/or other (e.g., physician office) records. The information that will be recorded will be limited to 
information concerning the outcome of your pregnancy.  
 
Note: Research outcomes from this study will not be stored in your medical records. 
 
Who will have access to identifiable information related to my participation in this research study? 
In addition to the investigators listed on the first page of this authorization (consent) form and their research 
staff, the following individuals will or may have access to identifiable information (which may include your identifiable 
medical information) related to your participation in this research study:  
 
Authorized representatives of the University of Pittsburgh Research Conduct and Compliance Office may 
review your identifiable research information (which may include your identifiable medical information) for the 
purpose of monitoring the appropriate conduct of this research study.  
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In unusual cases, the investigators may be required to release identifiable information (which may include 
your identifiable medical information) related to your participation in this research study in response to an order from 
a court of law. If the investigators learn that you or someone with whom you are involved is in serious danger or 
potential harm, they will need to inform, as required by Pennsylvania law, the appropriate agencies. 
 
Authorized representatives of the UPMC hospitals or other affiliated health care providers may have access 
to identifiable information (which may include your identifiable medical information) related to your participation in this 
research study for the purpose of (1) fulfilling orders, made by the investigators, for hospital and health care services 
(e.g., laboratory tests, diagnostic procedures) associated with research study participation; (2) addressing correct 
payment for tests and procedures ordered by the investigators; and/or (3) for internal hospital operations (i.e. quality 
assurance). 
 
For how long will the investigators be permitted to use and disclose identifiable information related to my 
participation in this research study? 
The investigators may continue to use and disclose, for the purposes described above, identifiable 
information (which may include your identifiable medical information) related to your participation in this research 
study for a minimum of seven years after final reporting or publication of a project.  
 
May I have access to my medical information that results from my participation in this research study? 
In accordance with the UPMC Notices of Privacy Practices document that you have been provided, you are 
permitted access to information (including information resulting from your participation in this research study) 
contained within your medical records filed with your health care provider. 
 
Is my participation in this research study voluntary? 
Your participation in this research study, to include the use and disclosure of your identifiable information for 
the purposes described above, is completely voluntary. (Note, however, that if you do not provide your consent for 
the use and disclosure of your identifiable information for the purposes described above, you will not be allowed to 
participate in the research study.) Whether or not you provide your consent for participation in this research study will 
have no effect on your current or future relationship with the University of Pittsburgh. Whether or not you provide your 
consent for participation in this research study will have no effect on your current or future medical care at a UPMC 
hospital or affiliated health care provider or your current or future relationship with a health care insurance provider. 
 
Your doctor (either Dr Emery, Hogge, Kolthoff, Rajovic or Simhan) is involved as a co-investigator in this 
research study. As both your doctor and a research investigator, s/he is interested both in your medical care and the 
conduct of this research study. Before agreeing to participate in this research study, or at any time during your study 
participation, you may discuss your care with another doctor who is not associated with this research study. You are 
not under any obligation to participate in any research study offered by your doctor. 
 
May I withdraw, at a future date, my consent for participation in this research study? 
You may withdraw, at any time, your consent for participation in this research study, to include the use and 
disclosure of your identifiable information for the purposes described above. Note, however, that if you withdraw your 
consent for the use and disclosure of your identifiable medical record information for the purposes described above, 
you will also be withdrawn, in general, from further participation in this research study. Any identifiable research or 
medical information recorded for, or resulting from, your participation in this research study prior to the date that you 
formally withdrew your consent may continue to be used and disclosed by the investigators for the purposes 
described above.  Should you withdraw your blood sample and chorionic villus/amniocentesis sample will be 
destroyed. 
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To formally withdraw your consent for participation in this research study you should provide a written and 
dated notice of this decision to the principal investigator of this research study at the address listed on the first page 
of this form. 
 
Your decision to withdraw your consent for participation in this research study will have no effect on your 
current or future relationship with the University of Pittsburgh. Your decision to withdraw your consent for participation 
in this research study will have no effect on your current or future medical care at a UPMC hospital or affiliated health 
care provider or your current or future relationship with a health care insurance provider. 
 
If I agree to take part in this research study, can I be removed from the study without my consent? 
It is possible but highly unlikely that you may be removed from the research study by the researchers. 
 
************************************************************************ 
VOLUNTARY CONSENT 
 
The above information has been explained to me and all of my current questions have been answered. I 
understand that I am encouraged to ask questions about any aspect of this research study during the course of this 
study, and that such future questions will be answered by a qualified individual or by the investigator(s) listed on the 
first page of this consent document at the telephone number(s) given. I understand that I may always request that my 
questions, concerns or complaints be addressed by a listed investigator.   
 
I understand that I may contact the Human Subjects Protection Advocate of the IRB Office, University of 
Pittsburgh (1-866-212-2668) to discuss problems, concerns, and questions; obtain information; offer input; or discuss 
situations in the event that the research team is unavailable.   
 
By signing this form, I agree to participate in this research study. A copy of this consent form will be given to 
me. 
 
________________________________________________________ 
Participant’s Signature    
 
 
_______________________________________________________  ___________ 
Printed Name of Participant      Date 
 
 
CERTIFICATION of INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation. Any questions the 
individual(s) have about this study have been answered, and we will always be available to address future questions 
as they arise.” I further certify that no research component of this protocol was begun until after this consent form 
was signed 
 
 
___________________________________  ________________________ 
Printed Name of Person Obtaining Consent  Role in Research Study 
 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent  Date  
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APPENDIX B: FIGURES 
FIGURES 
 
Figure 3. Chromosome 12 Microdeletion Analysis 
Reproduced with permission from Peters, D.G., et al., Noninvasive Prenatal Diagnosis of a Fetal 
Microdeletion Syndrome. NEJM, 2011. 365(19)., [72]. Copyright Massachusetts Medical Society 
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 Figure 4.  Chromosome 5: Maternal sample with plasma DNA control libraries 
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 Figure 5.  Chromosome 5: Maternal sample with placental DNA control libraries 
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 Figure 6.  Chromosome 5: Fetal sample (by CVS) with plasma DNA control libraries 
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 Figure 7.  Chromosome 5: Fetal sample (by CVS) with placental DNA control libraries 
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 Figure 8.  Chromosome 5: Maternal plasma sample with plasma DNA control libraries 
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 Figure 9.  Chromosome 5: Maternal plasma sample with placental DNA control libraries 
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